



US007964358B2

(12) **United States Patent**
Loughran et al.

(10) **Patent No.:** **US 7,964,358 B2**
(45) **Date of Patent:** **Jun. 21, 2011**

- (54) **SPHINGOSINE 1-PHOSPHATE RECEPTOR GENE, SPPR**
- (75) Inventors: **Thomas P. Loughran**, Hummelstown, PA (US); **Ravi Kothapalli**, Wesley Chapel, FL (US)
- (73) Assignee: **University of South Florida**, Tampa, FL (US)
- (*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 0 days.

(21) Appl. No.: **12/879,918**

(22) Filed: **Sep. 10, 2010**

(65) **Prior Publication Data**

US 2011/0021375 A1 Jan. 27, 2011

Related U.S. Application Data

- (63) Continuation of application No. 12/193,428, filed on Aug. 18, 2008, now abandoned, which is a continuation of application No. 11/653,811, filed on Jan. 16, 2007, now abandoned, which is a continuation of application No. 10/024,019, filed on Dec. 21, 2001, now Pat. No. 7,220,580.

- (60) Provisional application No. 60/257,119, filed on Dec. 22, 2000.

- (51) **Int. Cl.**
C12Q 1/68 (2006.01)
G01N 33/53 (2006.01)
- (52) **U.S. Cl.** **435/6; 435/7.1**
- (58) **Field of Classification Search** None
See application file for complete search history.

(56) **References Cited**

U.S. PATENT DOCUMENTS

7,220,580 B2	5/2007	Loughran et al.	
2003/0119111 A1*	6/2003	Lal et al.	435/69.1
2007/0105148 A1	5/2007	Loughran et al.	
2009/0181382 A1	7/2009	Loughran et al.	

FOREIGN PATENT DOCUMENTS

EP	1 149 907 A1	10/2001
WO	WO 97/00952 A2	1/1997
WO	WO 99/33972 A1	7/1999
WO	WO 99/46277 A1	9/1999
WO	WO 00/11166 A1	3/2000
WO	WO 00/31258 A2	6/2000
WO	WO 01/66742 A2	9/2001
WO	WO 02/57311 A3	7/2002

OTHER PUBLICATIONS

An et al., "Characterization of a Novel Subtype of Human G Protein-Coupled Receptor for Lysophosphatidic Acid*", *The Journal of Biological Chemistry* (1998), 273(14): 7906-7910.

An et al., "Signaling Mechanisms and Molecular Characteristics of G Protein-Coupled Receptors for Lysophosphatidic Acid and Sphingosine 1-Phosphate", *Journal of Cellular Biochemistry Supplements* (1998), 31:147-157.

Chen et al. "Discordant protein and mRNA expression in lung adenocarcinomas" *Molecular and Cellular Proteomics*, 2002, 1:304-313.

Database EMBL 'ONLINE! Dec. 6, 2000, retrieved from EBI Database accession No. af317676 XP002236901 abstract.

Database EMBL 'ONLINE! Oct. 8, 1999, retrieved from EBI Database accession No. AC011461 XP002236899 abstract.

Database EMBL 'ONLINE! Sep. 28, 2001, retrieved from EBI Database accession No. AX244600 XP002236900 abstract (Sequence 26 from Patent WO 01 66742).

Epstein and Butow, "Microarray technology—enhanced versatility, persistent challenge", *Current Opinion in Biotechnology* (2000), 11: 36-41.

Glickman et al., "Molecular Cloning, Tissue-Specific Expression, and Chromosomal Localization of a Novel Nerve Growth Factor-Regulated G-Protein-Coupled Receptor, nrg-1", *Molecular and Cellular Neuroscience* (1999), 14:141-152.

Haynes et al. "Proteome analysis: biological assay or data archive?" *Electrophoresis*, 1998, 19:1862-1871.

HLA et al., "Sphingosine-1-Phosphate Signaling via the EDG-1 Family of G-Protein-Coupled Receptors", *Annals New York Academy of Sciences* (2000), 905:16-24.

Hu et al. "Analysis of genomic and proteomic data using advanced literature mining" *J. Proteome Res.*, 2003, 2:405-412.

Im et al., "Characterization of a Novel Sphingosine 1-Phosphate Receptor, Edg-8*", *The Journal of Biological Chemistry* (2000), 275(19):14281-14286.

Im, D.S. et al. "Characterization of the human and mouse sphingosine 1-phosphate receptor, SIP5(Edg-8): Structure-activity relationship of sphingosine 1-phosphate receptors" *Biochem.*, 2001, 40:14053-060.

IM, D.S. et al. as cited in: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=nucleotide&list_uids=18141314&dopt=GenBank "1:NM_030760.Homo sapiens endo . . .", Jan. 13, 2002, p. 1-3.

IM, D.S. et al. as cited in: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=nucleotide&list_uids=18141314&dopt=GenBank "1:NM_030760[gi:13540516]", Dec. 10, 2001, p. 1-2.

Kothapalli, et al., "Characterization of Human Sphingosine-1-Phosphate Receptor Gene (SIP5) and its Differential Expression in LGL Leukemia", *Biochemica et Biophysica Acta* (2002), 117-123..

Kothapalli, R. et al. "Characterization of a novel human sphingosine-1-phosphate receptor gene (sppr) and its differential expression in LGL leukemia" *Blood: Gene Expression in Lymphoid Malignancy*, 2001, 98:3029. Kothapalli, R. et al. as cited in: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=nucleotide&list_uids=18033256&dopt=GenBank "1:AF331840.Homo sapiens SPPR . . .", Jan. 2, 2002, p. 1-2.

Kothapalli, R. et al. as cited in: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=nucleotide&list_uids=18033258&dopt=GenBank "1:AF331841.Homo sapiens SPPR . . .", Jan. 2, 2002, p. 1-2.

Kothapalli, R. et al. as cited in: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=nucleotide&list_uids=18033260&dopt=GenBank "1:AF331842.Homo sapiens SPPR . . .", Jan. 2, 2002, p. 1-2.

Malek, R. et al. "Nrg-1 belongs to the endothelial differentiation gene family of G protein-coupled sphingosine-1-phosphate receptors" *J. Biol. Chem.*, 2001, 276(8):5692-99.

Semenzato et al., The Lymphoproliferative Disease of Granular Lymphocytes: Updated Criteria for Diagnosis, *Blood* (1997), 89(1): 256-260.

* cited by examiner

Primary Examiner — Christine J Saoud

Assistant Examiner — Jon M Lockard

(74) *Attorney, Agent, or Firm* — Saliwanchik, Lloyd & Eisenschenk

(57) **ABSTRACT**

A novel sphingosine 1-phosphate receptor gene, herein termed sppr, and its splice variants. Sppr is up-regulated in LGL and is useful, for example, in the diagnosis and treatment of certain lymphoproliferative, neurodegenerative and autoimmune diseases.

7 Claims, 16 Drawing Sheets

Microarray

FIG. 1A LGL






FIG. 1B Normal



Expression of EST-1 in LGL Leukemia




FIG. 2

Northern Blot:

N=Normal, NA=Normal Activated

LGL = LGL Leukemia

EST-1 = Human Sphingosine 1-Phosphate receptor

BDE: 3.0 (544/182)

FIG. 3

Human sphingosine 1-Phosphate receptor
 LOCUS tmpseq1 2336 bp 4-DEC-2000
 SOURCE PBMCs (LGL)
 ORGANISM Human
 Unclassified.

FEATURES Location/Qualifiers
 source 1..2336
 CDS 10..1205,10..1206
 /note="predicted coding region"
 /translation="

MESGLLRPAPVSEVIVLHYNVTGKLRGARYQFGAGLRADAVVCLAVCAPIVLENLAULLV
 LGRNPRFRAPMFLLLGSLTLSOLLAGAAYAANILLSSPFLTKLSPALWFAREGGVVFALV
 ASVLSLLALALERSLTMARRGFAPVSSRGRITLMAAAAWGVSLLLGLLPALGNCLGRLLD
 ACSTVLPYAKAYVLFVDFVGLAAICALYARIYCVVRANARRLPARPGTAGTTSTRA
 RRRPRSLALLRSLVSVLLAFVACWGPLFLDLLLDVACPARTCPVLLQADPFLGLAMANSI
 LNPRIITLNRDLRHALRLVCCGRHSCGRDPSGGQSASAAEASGGLRRCLPPGLDGSF
 SCSERSSPQRDGLDTSOSTOSFGAPTAARTLVSEPAD"

BASE COUNT 461 a 679 c 701 g 495 t
 ORIGIN

1 gggggggccc tggagtggg gccgctggc cggggcggg tgagcggagt catcgtcctg
 61 cattacaact acaccggcaa gccccgggt ggcgctacc agccgggtgc cggcctggcg
 121 ccgacggccg tgggtgccc ggcggtggc gcccttcacg tgcctagagaa tctagccgtg
 181 tggttgggce cgggacggca cccgcttcc caccgtccca tgttccctgt cctggggcag
 241 cccacgttgc cggatctgct ggcaggcgc gccctaccg ccaacaacct actgtcgggg
 301 ccgctccacc tgaactgtc ccccgcttc tggctgcac gggagggagg cgtctctgtg
 361 gcactcactg cgtccgtgct gagcccccg gccatcgcc tggagggcag cctcaccatg
 421 gcgcgaaagg gggccggccc cgtctccagt cggggggcca cgtcggcgat ggcagcccgc
 481 gccctggggg tgcctgtgct cctcgggctc ctgcccggc tgggctggaa ttgcctgggt
 541 cgcctgggac cctgctccac tgtctggcg ctctaccgca aggcctaccg gctctctctg
 601 gctctgccc cgtggggcat cctggccggc atctgtgcac tctaccggcg catctaccgc
 661 caggtaccgc ccaaccggcg gcgctggcg gccacggccg ggcctgggg gaccacctcg
 721 atccggggcg gtggcaagcc gcgctggctg gccctgtctg gccacgctcag cgtggtgctc
 781 ctggcctttg tggcatgtg gggcccctc tctctgtctg tgtctctcga cgtggcgtgc
 841 cggggcggca cctgtctctg actcctgcag gccgatccct tctcgggact ggcctcggcc
 901 aactcacttc tgaaccccat cctctaccg ctccaccaac gcgacttgcg ccacggcctc
 961 ctggccttgg tctgtggcg ccgctggggc ctggcctgct gccctgcccc gggccttgat
 1021 tggggcggcg cggctgaggg ttcggggggc ctggcctgct gccctgcccc gggccttgat
 1081 gggagcttca ggggctggga ggcctcactg ccccagggcg acgggctgga caccagggcg
 1141 tccataggca gcccccgtgc accccagacc gccccggactc tggctaccga accggctgca
 1201 gactgacacc ctcggccccc gactgtcttc ccaagtctta cagacttgtt ctttttacc
 1261 aaaggaattt gtaggaaatg cagccaaagg tgcagtggga aaagatgca gggaaatgta
 1321 tccatgcagg gacccccacc aatgtgaaca aacagacaaa aaatctgtgc cctcgtggaa
 1381 ttgacttctc gcttgggaac acagaaaaga actcgtgtat gaaataatgg agatgatcc
 1441 agtgacaaac gacagagatg gtgatggggg tcagggaaga cctctctgca gaggtagtga
 1501 cctgtgatgt gagctgagac ctctgtctcg ggaagaccaa aagaaaagca tttcaggatg
 1561 agggaaatgc atggcacaag gccctgaggc tgaatgtgce ccatgtgttc taagaaatgc
 1621 agcgatctgc gcgtgcttgc agcagggacg gagggggaga atgggaggag acaaggagct
 1681 gaaggagtag tcccggagg accctgtggg tgatatagag gacttgcctt ttgctctgag
 1741 tgaggctggg gccatagaag ctctaaagca gaagagggac ttgcccataat ccaggtgatc
 1801 acaggtgctc tggggcctcc atgggaggtt gaaaaccaca gaaggtgaa gggggctgca
 1861 ctgagccaca ggaacaatga tggagatcc agccaagccc agaccccgtg gattctagat
 1921 agattttaga ggcaccagac agaattactg aggaattgag tgttaagatg gaataaagtt
 1981 atcaaggaca atggcaaggg tggggacccc ccaaatctga ctttgggaga ctcagccaaa
 2041 tccatctcgg taataaaaat tcttttttat tttcttttc tttctttctt cttttctttc
 2101 tttttttttt ttcaggttgg gatctgttgc tctgtcacc agcctggagt gcaatgggca
 2161 caattatagc caactggcgc cgggaactcc tgggatcaag cctggagctc ctgctccagc
 2221 ctccctagta gccgggacta caggcatgca ccaccatgcc cagttaataa aattctctca
 2281 aatgcacaaa aaaaaaaaaa aaaaaactcg agggggggcc cgttacccaa ttcgcc

Alignment of deduced Amino acid sequence with Nrg-1 and Edg-8 (rat genes)

```

Nrg-1      MESGLRPAFVSEVIVLHYHYTKIRGARYQFGAGLRADAACVLAFCVLENIHAVLIV
EDG-8      MESGLRPAFVSEVIVLHYHYTKIRGARYQFGAGLRADAACVLAFCVLENIHAVLIV
SPPR      MESGLRPAFVSEVIVLHYHYTKIRGARYQFGAGLRADAACVLAFCVLENIHAVLIV
          *****

Nrg-1      LGRHPRHAPHFLLGSLTLDLGAAYATNLLSGPLTLRLSPALWFAREGGVFVALA
EDG-8      LGRHPRHAPHFLLGSLTLDLGAAYATNLLSGPLTLRLSPALWFAREGGVFVALA
SPPR      LGRHPRHAPHFLLGSLTLDLGAAYATNLLSGPLTLRLSPALWFAREGGVFVALT
          *****

Nrg-1      ASVLSLAIATERHILTHARGPAPAAASRARTLAAHVAANGLLLTGLLPLGWHICLGRLE
EDG-8      ASVLSLAIALERHILTHARGPAPAAASRARTLAAHVAANGLSLLGLLPAIGWHICLGRLE
SPPR      ASVLSLAIALERSLTHARGPAPAVSSRGRTLAAHVAANGVSLIGLIPALGWHICLGRLLD
          *****

Nrg-1      ACSTVILPYAKAYLFCVLAFLGILAAICAAVARIYQVRAHARRLRAGPGSRRATSSSR
EDG-8      ACSTVILPYAKAYLFCVLAFLGILAAICAAVARIYQVRAHARRLRAGPGSRRATSSSR
SPPR      ACSTVILPYAKAYLFCVLAFLGILAAICAAVARIYQVRAHARRLRAGPGT-AGITSTR
          *****

Nrg-1      SRHPRSLALLRLLSVLLAFVACWGPVLELLLDVACPARACPVLLQADPFLGLAHANS
EDG-8      SRHPRSLALLRLLSVLLAFVACWGFLELLLDVACPARACPVLLQADPFLGLAHANS
SPPR      ARKPRSLALLRLLSVLLAFVACWGFLELLLDVACPARTCPVLLQADPFLGLAHANS
          *****

Nrg-1      LLNPIIYFTTRDLRHALLRLLCCGRGFCNDSSNLSLQKSPSAVGPSSGGLRRCLEPPTLD
EDG-8      LLNPIIYFTTRDLRHALLRLLCCGRGFCNDSSNLSLQKSPSAVGPSSGGLRRCLEPPTLD
SPPR      LLNPIIYFTTRDLRHALLRLLVCCGRHCCGRDPSGQQ-SASAAEASGG-LRRCLEPGLD
          *****

Nrg-1      RSSSPRHSFPQRDGMDSCTGSPGAAATNRLVDPDAD-
EDG-8      RSSSPRHSFPQRDGMDSCTGSPGAAATNRLVDPDAD-
SPPR      GSFSGRSRSPQRDGLDTSQTSFGAFTAARTIIVSEPAD
          * * * * *

SPPR: Nrg -85%
SPPR: Edg -86%
* - single, fully conserved residue
. - conservation of strong groups
. . - conservation of weak groups
~ - no consensus

```

FIG. 4

FIG. 5

Sphingosine-1- phosphate receptor.1
LOCUS tmpseq_1 1698 bp 30-OCT-2000
DEFINITION No definition line found.
ACCESSION tmpseq_1
VERSION
KEYWORDS .
SOURCE Unknown.
ORGANISM Unknown.
Unclassified.

FEATURES Location/Qualifiers
source 1..1698
CDS 11..775,11..775
/note="predicted coding region"
/translation="MESGLLRPAPVSEVIVLHYNYTKGLRGARYQPGAGLRADAVVCL
AVCAFIVLENLAVLLNLGRHFRFHAPMFLLLGSLTLSVPARPGTAGTTSTRARRKPRS
LALLRRLSVLLAFVACWGPLFLLLLLDVACPARTCPVLLQADPFLGLAMANSLLNPI
IYTLNRLRLHALLRLVCCGRHSCGRDPSGSQQSASAAEASGGLRRLCLPPGLDGSFSG
SERSSPQRDGLDTSGSTGSPGAPTAARTLVSEPAAD"

BASE COUNT 352 a 462 c 516 g 368 t

ORIGIN
1 cgcgcggccc atggagtcgg ggctgctgcg gccggcgccg gtgagcgagg tcctcgtcct
61 gcattacaac tacaccgcca agctccggcg tgcgcgctac cagccgggtg ccggcctgcg
121 cgcgcgacgc gtgggtgycg tggcgggtgtg cgccttcata gtgctagaga atctagccgt
181 gttgttggtg ctggagccc acccggcgtt ccacgcctcc atgttctctgc tcctgggcag
241 cctcacgttg tgggtgccc caaggccccc gactgcccgg accacctcga ccggggcgcg
301 tegcaagccg cgtcgtctgg ccttgcctgg caagctcagc ggggtgctcc tggcctttgt
361 ggcattgttg ggcctctct tcttgcctgc gttgctcagc gggcgtgccc cggcgcgcac
421 ctgtctctgt cctctgtagg ccgatacctt cctgggactg gccatggcca actcaactct
481 gaaccccatc atctacaagc tcaccaaccg cgacctgcgc cagcgcctcc tgcgcctggt
541 ctgctgcgga cgcacctctt gcggcagaga ccggagtggc tcccagcagt cggcgagcgc
601 ggtctgaggt tccgggggccc tgcgcgcctg cctgcccccg ggccttgatg ggagctcag
661 cggctcggag cgtctatcgc cccagcgcga cgggctggac accagcggct ccacaggcag
721 ccccggtgca cccacagccc cccggactct ggtatcagaa ccggctgcag actgacacct
781 toggcccacg actgctctcc caagttttac agacttgttc tttttacata aaggatcttg
841 taggaatgca agccaaaagg ccagtcggaa aagatgcagc ggaatgtat ttatgcagcg
901 acaccccaca atgtgaacaa acagacaaaa aatctgtgcc ctctggaat tgactcttg
961 cttgggaaca cagaaaagaa ctgggtgacg aaataatgga gatgattcca gtgacaaacg
1021 acagagatgg tgatgggtgg cagggaaagc ctctctgcag aggtagtgc ttgtgatgtg
1081 agctgagacc tctctcctgg gaagaccaaa agaaaagcat ttcaggatga gggaatggca
1141 tgcgcaaaagg ccttgaggct gaaatgtgccc catgtgtctc aagaaatgca gcgatgctgg
1201 tctgctctga gcagggaagg agggggagaa tgggaggaga caaggagctg aaggagtgt
1261 ccccgaaagg ccttgtgggt gatatagagg acttgccttc tgcctctgagt gaggtgggag
1321 ccacagaagc ttctaagcag aagagggact tgccttaatt caggtgatca caggtgtctt
1381 gtggcctcca tgggaggttg aaaaccagag aaggtsaagg ggggctgccc tgagccacag
1441 gaacaatgat ggagattcca gctaagccca gaccccgctg attctagata gatcttagag
1501 gcagcagaca gaattactga ggaattgagt gtaagagtgg aatcaagtta tcaaggacaa
1561 tgccaagggc ggggcacccc caaatttjac tctgggagac tcagccaaa cctatctggt
1621 aataaaaattt cttttttatt tctctctctt tctctctctt cttttttttt tttttgaggt
1681 gggatctctt gctctgtc

FIG. 6

Springosine -1-Phosphate receptor 2


```

LOCUS      tmpseq_1      1245 bp                      30-OCT-2000
DEFINITION No definition line found.
ACCESSION  tmpseq_1
VERSION
KEYWORDS
SOURCE     Unknown.
ORGANISM   Unknown.
           Unclassified.
FEATURES   Location/Qualifiers
           source       1..1245
           CDS          11..322,11..322
                        /note="predicted coding region"
                        /translation="MESGLLRPAPVSEVIVLHYNMTGKLRGARYQPGAGLRADAVVCL
                        AVCAFIVLENLAVLLVLRHPRFHAPMFLLLGSLTSLDLLAGAAAYAAAARTLVSEPAAD"
BASE COUNT      298 a      284 c      372 g      291 t
ORIGIN
1  cggcggggccc atggagtggg ggtgctgcg gccggcgcg gtgagcgagg tcatcgtcct
61 gcattacaac tacaccggca agctccggg tgcgctctac cagccgggtg ccggcctggc
121 cgcgagcgcc gtggtgtgcc tggcgggtg cgccttcctc gtgctagaga atctagecgt
181 gttgttgggtg ctgggacgcc acccggcctt ccacgctccc atgttcctgc tcttgggcag
241 cctcaegttg tgggatctgc tggcaggcgc cgcctacgcc gccgcggccc ggaactctggt
301 atcagaaccg gctgcagact gacaccctcg gcccacgact gtcttcccaa gttttacaga
361 cttgttcttt ttacataaag gaattttagt gaaatgcagc caaagggtgca gtgggaaaag
421 atgcagggga aatgtattta tgcagcgaca ccccacaatg tgaacaaaac gacaaaaaat
481 ctgtgcccctc gtggaattga cgttctgctt gggaacacag aaaagaactc ggtgatgaaa
541 taatggagat gattccagtg acaaacgaca gagatggtga tgggtggtcag ggaagacctc
601 tctgcagagg tagtgacttg tgatgtgagc tgagacctct gtcttgggaa gaccaaaaga
661 aaagcatttc aggatgaggg aatggcatgc gcaaaggccc tgagggtgaa atgtgcccct
721 gtgtttctaag aaatgcagcg atgctggtgt gccctggagca gggacggagg gggagaaatgg
781 gaggagacaa ggagctgaag gagtgttccc cgaaggacct tgtgggtgat atagaggact
841 tggcttttgc tctgagtgag gtgggagcca tagaagcttc taagcagaag agggacttgc
901 cctaattcag gtgatccacg gtgtcttgtg gccctccatgg gaggttgaaa accagagaag
961 gtgaaggggg gctgcactga gccacaggaa caatgatgga gattccagct aagcccagac
1021 cccgtggatt ctagatagat tttagaggca gcagacagaa ttactgagga attgagtgta
1081 agagtggaaat aaagtta tca aggacaatgc caagggctggg gcaccccaaa atttgactct
1141 gggagactca gccaaat tct atctggtaat aaaatttctt ctttattttt cttttctttc
1201 ttttttttct tttttttttt ttgagttggg atcttbtgct ctgctc

```

FIG. 7

Expression of *Sppr* in Human Tissues



1 gcgcgcccacatcgagtcggggctgctgcggccggcggccgggtgagcgagggtcatcgtcctg 17
 M E S G L L R P A P V S E V I V L
 61 cattacaactacaccggcaagetccgcgggtgcgcgctaccagccgggtgccggcctgccc 37
 H Y N Y T G K L R G A R Y Q P G A G L R
 121 gcgcgacgcgtgggtgtgcccggcggtgccccttcacgtgctagagaatctagccgtg 57
 A D A V V C L A V C A F I V L E N L A V
 181 ttgttggtgctcgggaaccaccgcgcttcacgctcccattgctcctgctcctgggcagg 77
 L L V L G R H P R F H A P M F L L L G S
 241 ctcacggttgctgggatctgctggcaggcgcgcgctacgcgcgaacatcctactgtcgggg 97
 L T L S D L L A G A A Y A A N I L L S G
 301 ccgctcacgctgaaactgtccccgcgctctggttcgcacgggagggaggcgtcttcgtg 117
 P L T L K L S P A L W F A R E G G V F V
 361 gcactcaactgcgtccgtgctgagcctcctggccatcgcgctggagcgcagcctcaccatg 137
 A L T A S V L S L L A I A L E R S L T M
 421 gcgcgacggggggccgcgcgctccagtcgggggcgcacgcctggcgatggcagccgcg 157
 A R R G P A P V S S R G R T L A M A A A
 481 gcctggggcgtgtcgtgctcctcgggctcctgcacgcgctgggctggaattgctgggt 177
 A W G V S L L L G L L P A L G W N C L G
 541 cgctggacgcttgcctcactgtcttgccgctctacgccaaggcctacgtgctctctctgc 197
 R L D A C S T V L P L Y A K A Y V L F C
 601 gtgctcgccttctgctggcctcctggcgcgctcctgctgactcctacgcgcgctcctactgc 217
 V L A F V S I L A A I C A L Y A R I Y C
 661 caggtaacgcgcacaacgcgcggcgcctgcggcgcagggcccgggactgcggggaccacctcg 237
 Q V R A N A R R L P A R P G T A G T T S
 721 accgggcgcgctgcgaagcgcgctcctgctggccttgcctgctgcccagcctcagcgtggctc 257
 T R A R K P R S L A L L R T L S V V I
 781 ctggcctctgtggaatgtggggcccccctctcctgctgctgctgctgctgctgctgctgctg 277
 L A F V A C W G P L F L L L L L D V A C
 841 cggcgcgcacactgtcctgtaactcctgcagcgcgacccctcctcctgggactggccatggcc 297
 P A R T C P V L L Q A D P F L G L A M A
 901 aactcaacttctgaaccccacatctacacgctcaccacccgcgacctgcgccacgcgctc 317
 N S L L N P I I Y T L T N R D L R H A L
 961 ctgcgcctggctgctgctgaggacgcactcctgcccagagaccggagtggtcccagcag 337
 L R L V C C G R H S C G R D P S G S Q Q
 1021 tggcgagcgcggctgaggtctccgggggctgcgcgctgctgccccgggctctgat 357
 S A S A A E A S G G L R R C L P P G L D
 1081 gggagctcagcggctcggagcctcctcctcagcgcgagggctggacaccagcgcg 377
 G S F S G S E R S S P Q R D G L D T S G
 1141 tcacacaggcagccccgggtgcaccacagcgcgcgggactctgggtatcagaaccgctgca 397
 S T G S F G A P T A A R T L V S E P A A
 1201 gactgacaccctcggcccacgactgtcttcccaagttttacagacttggtctttttacat 398
 D *
 1261 aaaggaatttgtaggaatgcagccaaaggtgcagtcggaaaagatgcaggggaaatgta
 1321 tttatgcagcgcacccccacaatgtgaacaaacagacaaaaaatctgtgccctcgtggaa
 1381 ttgacgtctctgcttggaacacagaaaagaactcgggtgatgaaataatggagatgattcc
 1441 agtgacaaaacagacagagatgggtgatgggtggtcagggaagacctctctgcagaggtagtga
 1501 cttgtgatgtgagctgagacctctgtcctgggaagacaaaaagaaaagcatttcaggatg
 1561 agggaatggcatgcgcaaaaggccctgaggctgaaatgtgcccattgttctaaagaaatgc
 1621 agcgatgctgggtgctcctggagcaggcagggaggggagaaatgggaggagacaaggagct
 1681 gaaggagttagttccgaaggacctgtgggtgatagaggacttcgcttttgcctctgag
 1741 tgagggtgggagccatagaagctctaaagcagaagaggacttgccctaattcagggtgatc
 1801 acagggtgcttgtggcctccatgggaggttgaaaaaacacagaaggtgaagggggctgca
 1861 ctgagccacaggaaacaatgatggagattccagctaagcccagaccccgtggattctagat
 1921 agattttagaggcagcagacagaattactgaggaattgagtgtagagtggaataaagtt
 1981 atcaaggacaatgcaagggtggcgcacccccaaaatgtgactttggcagactcagccaaa
 2041 tcctatctggtaataaaaatctctttttatctttctttctttctttctttctttctttct
 2101 tttttttttttttgagttgggatcttgtgctctgtcaccagggctggagtgcaatgggca
 2161 caattatagctcactgcagcctggaactcctgggatcaagcctggagtccctgctcagc
 2221 ctccctagtagctgggactacagcctgcaccaccatgcccagttataaaaaatctcttca
 2281 aatgcaaaaaaaaaaaaaaaaaaaaaa

FIG. 8

NRG-1 MESGLLRPAPVSEVIVLHYNITGKLRGARYQPGAGLRADA AVCLAVCAFIVLENLAVLLV
 EDG-β MESGLLRPAPVSEVIVLHYNITGKLRGARYQPGAGLRADA AVCLAVCAFIVLENLAVLLV
 SIP₅ MESGLLRPAPVSEVIVLHYNITGKLRGARYQPGAGLRADA VVCLAVCAFIVLENLAVLLV

NRG-1 LGRHPRFHAPMFLLLGS LTLSDLLAGAAAYATNILLSGPLTLRLSPALWFAREGGVFVALA
 EDG-β LGRHPRFHAPMFLLLGS LTLSDLLAGAAAYATNILLSGPLTLRLSPALWFAREGGVFVALA
 SIP₅ LGRHPRFHAPMFLLLGS LTLSDLLAGAAAYAANILLSGPLTLKLSPALWFAREGGVFVALT
 *****;*****;*****;

NRG-1 ASVLSLLAIAIERH LTMARRGPAPAASRARTLAMAVA AWGLLLTLG LLLPALGWNCLGRLE
 EDG-β ASVLSLLAIALERH LTMARRGPAPAASRARTLAMAVA AWGLS LLLG LLLPALGWNCLGRLE
 SIP₅ ASVLSLLAIALERS LTMARRGPAPVSSRGR TLAMAAA AWGVS LLLG LLLPALGWNCLGRLD
 *****; * *****; * *****; * *****; * *****;

NRG-1 ACSTVLPVYAKAYV LFCVLAFLGILAAICALYARIYCQVRANARRLRAGPGSRRATSSSR
 EDG-β ACSTVLPVYAKAYV LFCVLAFLGILAAICALYARIYCQVRANARRLRAGPGSRRATSSSR
 SIP₅ ACSTVLPVYAKAYV LFCVLAFLV GILAAICALYARIYCQVRANARRLPARP GT-AGTTSTR
 *****;*****;***** * **; .:;*

NRG-1 SRHTPRSLALLR TLSVLLAFVACWG PLF LLL LLDVACPARACPVLLQAD PFLGLAMANS
 EDG-β SRHTPRSLALLR TLSVLLAFVACWG PLF LLL LLDVACPARACPVLLQAD PFLGLAMANS
 SIP₅ ARRKPRSLALLR TLSVLLAFVACWG PLF LLL LLDVACPARTCPVLLQAD PFLGLAMANS
 :*; .*****;*****;*****;

NRG-1 LLNP I IYTF TNRDLRHALLRLCCGRGPCNQDSSNSLQ RSPSAVGPSSGG LRRCLPPTLD
 EDG-β LLNP I IYTF TNRDLRHALLRLCCGRGPCNQDSSNSLQ RSPSAVGPSSGG LRRCLPPTLD
 SIP₅ LLNP I IYTL TNRDLRHALLRLVCCGRHSCGRDP SGGSQQ-SASAAEASGG-LRRCLPPGLD
 *****;*****;*** .:;*. * * * . * * * . * * * ***** *

NRG-1 RSSSPSEHSCPQRDGM DTSCTGSPGAATANRTLVPDATD-
 EDG-β RSSSPSEHSCPQRDGM DTSCTGSPGAATANRTLVPDATD-
 SIP₅ GSFSGSERSSPQRDGLD TSGSTGSPGAPTAARTLVSEPAAD
 * * *; * .*****;*** *****.* * *****.:.:

SIP₅: Nrg - 85%
 SIP₅: ECG - 86%
 * - single, fully conserved residue
 : - conservation of strong groups
 . - conservation of weak groups
 - no consensus

FIG. 9




FIG. 10




FIG. 11

SIP₅ MESGLLRPAPVSEVIVLHYNVTGKLRGARYQPGAGLRADAVVCLAVCAFIVLENLAVLLV
SIP₅-α MESGLLRPAPVSEVIVLHYNVTGKLRGARYQPGAGLRADAVVCLAVCAFIVLENLAVLLV

SIP₅ LGRHPRFHAPMFLLLGSLTLLSDLLAGAAAYAANILLSGPLTLKLSPALWFAREGGVFVALT
SIP₅-α LGRHPRFHAPMFLLLGSLTLLS-----

SIP₅ ASVLSLLAIALERSLTMARRGPAPVSSRGRRTLAMAAAAGVSLLLGLLPPALGWNCGLGRLD
SIP₅-α -----
SIP₅ ACSTVLPYAKAYVFCVLA FVGI LAICALYARIYCQVRANARRLPPARPGTAGTTSTRA
SIP₅-α -----VPARPGTAGTTSTRA
:*****
SIP₅ RRKPRSLALLRRLSVLLAFVACWGPLFLLLLLDVACPARTCPVLLQADPFLGLAMANSL
SIP₅-α RRKPRSLALLRRLSVLLAFVACWGPLFLLLLLDVACPARTCPVLLQADPFLGLAMANSL

SIP₅ LNP I IYTLTNRDLRHALLRLVCCGRHSCGRDPSGSQQSASAAEASGGLRRCCLPPGLDGSF
SIP₅-α LNP I IYTLTNRDLRHALLRLVCCGRHSCGRDPSGSQQSASAAEASGGLRRCCLPPGLDGSF

SIP₅ SGSESSPQRDGLDTSGSTGSPGAPTAARTLVSEPAAD
SIP₅-α SGSESSPQRDGLDTSGSTGSPGAPTAARTLVSEPAAD

FIG. 12A

SIP₅ MESGLLRPAPVSEVIVLHNYTGKLRGARYQPGAGLRADAVVCLAVCAFI VLENLAVLLV
SIP₅-β MESGLLRPAPVSEVIVLHNYTGKLRGARYQPGAGLRADAVVCLAVCAFI VLENLAVLLV

SIP₅ LGRHPRFHAPMFLLLGSLTSLDLAGAAYAANILLSGPLTLKLSPALWFAREGGVFVALT
SIP₅-β LGRHPRFHAPMFLLLGSLTSLDLAGAAYAA-----

SIP₅ ASVLSLLAIALERSITMARRGPAPVSSRGRITLAMAAAANGVSLLLGLLPALGWNCCLGRLD
SIP₅-β -----

SIP₅ ACSTVLPYAKAYVLCVLAFCVLAIVGILAAICALYARIYCQVRANARRLPARPGTAGTSTRA
SIP₅-β -----

SIP₅ RRKPRSLALLRTL SVVLLAFVACWGPLFLLLLLDVACPARTCPVLLQADPFLGLAMANSL
SIP₅-β -----

SIP₅ LNPIIYTLTNRDLRHALLRLVCCGRHSCGRDPFSGSQSASAAEASGGLRRCLPPGLDGSF
SIP₅-β -----

SIP₅ SGSESSPQRDGLDTSGSTGSPGAPTAAARTLVSEPAAD
SIP₅-β -----AARTLVSEPAAD

FIG. 12B




FIG. 13

SIP MESGLLRPAPVSEVIVLHYNITKLRGARYQPGAGLRADAVVCLAVCAFIIVLENLAVLLV
SIP2 MESGLLRPAPVSEVIVLHYNITKLRGARYQPGAGLRADAVVCLAVCAFIIVLENLAVLLV

SIP LGRHPRFHAPMFLLLGSLTSLDLAGAAYAANILLSGPLTLKLSPALWFAREGGVFVALT
SIP2 LGRHPRFHAPMFLLLGSLTSLDLAGAAYAA-----

SIP ASVLSLLAIALERSLTMARRGPAPVSSRGETLAMAAAAGVSLLLGLLPALGWNCIGFLD
SIP2 -----

SIP ACSTVLPYAKAVLFCVLAFFVILAAICALYARIYCQVRANARRLPARPGTAGTSTRA
SIP2 -----

SIP RRRKPRSLALLRRTLSVLLAFVACWGPLFLLLLLDVACPARTCPVLLQADPFLGLAMANSI
SIP2 -----

SIP LNPIIVTLTNRDLRHALLRLVCCGRHSCGRDPSGSQASASAAEASGGLRRCLP PGLDGSF
SIP2 -----

SIP SGSESSPQRDGLDTSGSTGSPGAPTAARTLVSEPAAD
SIP2 -----AARTLVSEPAAD

FIG. 15

SPHINGOSINE 1-PHOSPHATE RECEPTOR GENE, SPPR

CROSS REFERENCE TO RELATED APPLICATIONS

The present application is a continuation of U.S. application Ser. No. 12/193,428, filed Aug. 18, 2008, which is a continuation of U.S. application Ser. No. 11/653,811, filed Jan. 16, 2007, now abandoned, which is a continuation of U.S. application Ser. No. 10/024,019, filed Dec. 21, 2001, now U.S. Pat. No. 7,220,580, which claims benefit of U.S. Provisional Application Ser. No. 60/257,119, filed Dec. 22, 2000, each of which is hereby incorporated by reference herein in its entirety, including any figures, tables, nucleic acid sequences, amino acid sequences, and drawings.

FIELD OF THE INVENTION

The present invention relates to the genetics of autoimmune diseases, including lymphoproliferative diseases, such as large granular lymphocyte leukemia (LGL), and rheumatoid arthritis (RA). Specifically, the invention relates to a novel sphingosine 1-phosphate receptor gene, herein termed *sppr*, and its splice variants. *Sppr* is up-regulated in LGL and is useful, for example, in the diagnosis and treatment of certain lymphoproliferative, neurodegenerative and autoimmune diseases.

BACKGROUND OF THE INVENTION

Large granular lymphocyte leukemia (LGL) is a rare form of lymphoproliferative disorder often associated with autoimmune disease (Loughran T. P., Clonal diseases of large granular lymphocytes. Blood 82, 1-14, 1993).

The cause of LGL is still not fully understood. An increased count of large granular lymphocytes is characteristic of LGL leukemia. Patients with clonal CD3+LGL, as determined by cytogenetic or T-cell receptor (TCR) gene rearrangement studies, are classified as T-LGL. Some of these patients may resemble those with Felty's syndrome with clinical features of rheumatoid arthritis, neutropenia and splenomegaly (Ahem M. J., et al., P. Phenotypic and genotypic analysis of mononuclear cells from patients with Felty's syndrome. Ann. Rheum. 49, 103-108, 1990.) Morbidity and mortality in patients with LGL leukemia typically results from infections acquired during severe neutropenia.

The etiology of LGL leukemia is also not yet known. There is strong evidence that suggests that leukemic large granular lymphocytes are antigen activated cytotoxic T lymphocytes (CTL), but the nature of the antigen and of the initial stimulus leading to antigen driven expansion are not known.

LGL leukemic cells express FAS and FAS ligand, but they are not actively undergoing apoptosis (Perzova, R and Loughran, T. P., Jr. Constitutive expression of Fas ligand in large granular lymphocyte leukemia. British Jnl. Haematology, 1997). How they acquire resistance to apoptosis is not known.

Within the field of the diagnosis and treatment of LGL and other autoimmune diseases, there is a need for better tools for diagnosis and early detection of disease, specific therapeutic targets and treatments for the disease, and more specific reagents and tools with which to identify the pathogenic pathways of these diseases. The present invention provides a novel gene and splice variants that are linked to these diseases, and which address the aforementioned needs and more, as will become clear to one of skill in the art upon reading the following disclosure.

SUMMARY OF THE INVENTION

Large granular lymphocyte leukemia (LGL) is a lymphoproliferative disorder often associated with autoimmune disease. In order to identify differentially expressed genes in LGL leukemia, microarray analysis is performed from RNA isolated from PBMC of LGL leukemia patients and compared with normal healthy individual(s). By screening a human LGL leukemia library the full-length sequence of a human gene that showed 85% identity with rat sphingosine 1-phosphate receptor is obtained. Two different isoforms are also identified by RT-PCR, designated sphingosine 1-phosphate receptor 1, also referred to as S1p5- α and sphingosine 1-phosphate receptor 2, also referred to as S1P5- β . Sphingosine 1-phosphate receptor (*sppr*) is present in brain, spleen, PBMCs, liver and kidney. The present inventors found it is over-expressed in LGL leukemia patients when compare to normal individuals.

In a first embodiment, the invention provides a gene comprising *sppr* or a splice 5 variant, or *sppr* protein or modified proteins or fragments thereof.

In a further embodiment, the invention provides a nucleic acid capable of hybridizing to at least a portion of said *sppr* gene, including splice variants.

In a further embodiment, the invention provides methods for screening for autoimmune diseases, including LGL or rheumatoid arthritis, based on overexpression of *sppr*.

In a further embodiment, the invention provides for monoclonal antibodies to *sppr* and their use in detection, diagnosis and treatment of disease states.

In a further embodiment, the invention provides for screening of ligands, agonists, and antagonists of *sppr*.

In a further embodiment, the invention provides for inhibition or treatment of neurodegenerative disease.

In a preferred embodiment the present invention provides a sphingosine 1-phosphate receptor gene. The use of said gene makes it possible to produce the sphingosine 1-phosphate receptor protein with ease and in large quantities, and said protein, which has sphingosine 1-phosphate receptor activity, can be used in developing therapeutic agents for various diseases.

Throughout this document the nomenclature *sppr* and S1P5 are used interchangeably. The receptor was initially termed *sppr*. However, to be consistent with a new nomenclature system this receptor was renamed S1P5.

DESCRIPTION OF THE FIGURES

FIG. 1A-B illustrates a microarray of the differential expression of the selected EST. (EST (GenBank ID 1868427) is obtained Incyte Genomics.) FIG. 1A-B shows a microarray hybridized with the fluorescent labeled probes generated using mRNA isolated from PBMC of LGL leukemia patient and from mRNA isolated from normal healthy individual. FIG. 1A illustrates a microarray showing the expression of an LGL leukemia patient cDNAs. FIG. 1B illustrates a microarray showing the expression of a normal healthy individual. Arrows show the expression of EST in both patient and normal individual (GeneBank Id: N47089). Intensity bar shows the increased expression starting from left to right. A balanced differential expression of 3.0 is determined for this EST.

FIG. 2 shows Northern blot analysis performed with 10 μ g of total RNA isolated from PBMC of LGL leukemia patients and normal healthy individuals. These results demonstrate

over-expression of EST in the PBMCs of LGL leukemia when compared to normal and normal activated PBMCs of healthy individuals.

FIG. 3 shows the complete nucleotide sequence, SEQ ID NO: 4, of human sphingosine 1-Phosphate receptor (SPPR) cDNA and amino acid sequence (SEQ ID NO: 3) as predicted by the nucleic acid sequence. The full-length (2.2 kb) nucleotide sequence of *sppr* is compiled from sequences of clones isolated from an LGL leukemia library and RT-PCR products obtained by using the gene specific primers designed using the corresponding sequence from chromosome 19.

FIG. 4 shows the alignment of the amino acid sequence of SPPR with other members of the sphingosine 1-phosphate receptor family. The deduced amino acid sequence of *sppr* is compared with rat *edg-1* and *nrg-1*. There is approximately 85% identity with these genes.

FIG. 5 shows the nucleotide sequence and deduced amino acid sequence of splice variant, sphingosine 1-phosphate receptor 1. 1.6 kb fragment is obtained by RT-PCR using total RNA isolated from PBMC of an LGL leukemia patient. The fragment is then cloned and sequenced.

FIG. 6 shows the nucleotide sequence and deduced amino acid sequence of splice variant, sphingosine 1-phosphate receptor 2. The nucleotide sequence of an alternative splice variant of *sppr* and deduced sequence. 1.2 kb fragment is obtained from RT-PCR using total RNA isolated from PBMC of LGL leukemia. The fragment is then cloned and sequenced.

FIG. 7 shows results of *sppr* Northern blot analysis with different tissues. Northern blot analysis is performed using a multiple tissue Northern blot (Clontech). Northern blots contain approximately 1 μ g of poly A+ per lane from twelve different human tissues. A 1.5 kb fragment containing the full-length open reading frame for *sppr* is used as a probe. Results show *sppr* is expressed in mainly brain, spleen, and peripheral blood leukocytes. Small amounts of *sppr* are also expressed in lung, placenta, liver and kidney.

FIG. 8 shows nucleotide and deduced amino acid sequence of human $S1P_5$ cDNA. Full-length (2.2 kb) nucleotide sequence of $S1P_5$ is compiled from the sequences of clones isolated from LGL leukemia library (clone 6) and RT-PCR products. GenBank Accession No. AF331840. The predicted amino acids of the coding region are shown underneath by a single letter abbreviation. The left side of the sequence shows nucleotide numbers and the right side shows amino acid numbers. Possible seven transmembrane helices are underlined. The putative polyadenylation sites are in bold.

FIG. 9 shows Alignment of the deduced amino acid sequence of $S1P_5$ with other members: The deduced amino acid sequence of $S1P_5$ is compared with predicted amino acid sequences of rat *edg-8* and *nrg-1*. There is approximately 86% identity with these genes. *—single, fully conserved residue, :—conservation of strong groups, .—conservation of weak groups, —no consensus.

FIGS. 10A-10C show activation of Erk2 by $S1P_5$ in HEK293 cells transiently transfected with $S1P_5$. HEK 293 cells transfected with the HA-ERK2 plasmid (0.2 μ g) and either pcDNA $S1P_5$ (0.5 μ g) or vector alone. Vector plasmid is added to each transfection reaction to equalize the amount of total DNA (2.1 μ g). After serum-starvation, the cells are treated with 1 μ M $S1P_5$ or 1 μ M LPA for 5 min (BSA was added to the controls). HA-ERK2 is immunoprecipitated from one half of each whole cell lysate and used for measuring the kinase activity utilizing MBP as substrate, while HA-ERK2 immunoprecipitated from the other half is used for determining the amount of ERK2 protein in the immune complex. FIG. 10A illustrates a representative autoradiogram

of ^{32}P incorporation into MBP catalyzed by HA-ERK 2 immunoprecipitated from transiently transfected cells treated as indicated. FIG. 10B illustrates the corresponding Western blot demonstrating the amount of HA-ERK2 present in each of the immune complexes. FIG. 10C illustrates a plot of ERK 2 activity (fold) normalized to the amount of ERK2 protein (means \pm SD from three independent experiments).

FIG. 11 shows Northern blot analysis of $S1P_5$ mRNA expression in PBMC of LGL leukemia patients and normal healthy individuals. Northern blot is performed with 10 μ g of total RNA isolated from PBMC of LGL leukemia patients and normal healthy individuals. LGL=LGL leukemia patients, N=Normal healthy individual, NA=Normal healthy individuals PBMCs activated by IL2 and PHA. These results demonstrate over-expression of $S1P_5$ in the PBMC of LGL leukemia when compared to normal and normal activated. PBMC of healthy individuals.

FIG. 12A-B shows comparison of the predicted amino acid sequences of $S1P_5$, $S1P_5$ - α and $S1P_5$ - β . The predicted amino acid sequences are aligned using CLUSTAL program. FIG. 12A illustrates the nucleotide sequence of an alternative splice variant of $S1P_5$ - α and deduced amino acid sequence. A 1.6 kb fragment is obtained from RT-PCR using total RNA isolated from PBMC of LGL leukemia patient. This fragment is cloned and sequenced. FIG. 12B illustrates the nucleotide sequence of an alternative splice variant of $S1P_5$ - β and deduced sequence. A 1.2 kb fragment is obtained from RT-PCR using total RNA isolated from PBMC of LGL leukemia. This fragment is cloned and sequenced.

FIG. 13 shows tissue distribution of $S1P_5$ message. Northern blot analysis is performed using the multiple tissue blot obtained from Clontech. The Northern Blot contains approximately 2 μ g of poly per lane from twelve different human tissues and a 1.5 kb fragment containing the full-length open reading frame of $S1P_5$ is used as a probe. As shown above, $S1P_5$ is expressed mainly in brain, spleen, and peripheral blood leukocytes. Trace amounts of $S1P_5$ are also expressed in lung, placenta, liver and kidney. (Please note: Signals are significantly stronger in normal tissue on poly A+RNA Northern blot compared to total RNA Northern blot.)

DETAILED DESCRIPTION OF THE INVENTION

The abbreviations for amino acids, peptides, base sequences, nucleic acids and so forth as used herein in the present specification are those recommended by the International Union of Pure and Applied Chemistry (IUPAC) and the International Union of Biochemistry (IUB) and in the "Guidelines for drafting patent specifications relative to base sequences and/or amino acid sequences" edited by the Japanese Patent Office or those commonly used in the relevant field of art.

Although the genes of the present invention is represented by a single-stranded DNA sequence, as shown under, for example, SEQ ID NO:4, the present invention also includes the DNA sequence complementary to such a single-stranded DNA sequence as well as a component comprising both of these. The DNA sequence representing the gene of the present invention shown in the above-mentioned SEQ ID NO: 4 is an example of the codon combination coding for the respective amino acid residues according to the amino acid sequence shown in SEQ ID NO:7. The gene of the present invention is not limited to the above-mentioned one but may, of course, have any other DNA base sequence comprising a combination of codons arbitrarily selected for the respective amino acid residues without altering the above-mentioned amino acid sequence. Selection of said codons can be carried out by

the conventional method in which the codon usage or codon choice in the host to be used for gene recombination is taken into consideration [Nucl. Acids Res., 9, 43-74 (1981)], and these codons can be produced, for example by chemical synthesis, etc.

The gene of the present invention further includes DNA sequences coding for those equivalents to the above-mentioned amino acid sequence that are derived from the latter by deletion, addition or like modification of one or more amino acid residues or part of the amino acid sequence and have similar sphingosine 1-phosphate receptor activity to that of the sphingosine 1-phosphate receptor protein. While production, alteration (mutation) or the like of these polypeptides may occur spontaneously, they can also be produced by post-translational modification. Furthermore, any desired gene can be produced by gene engineering techniques such as the site-specific mutagenesis technique in which the natural gene (gene of the present invention) is altered, by a chemical synthesis technique such as the phosphite triester method in which mutant DNAs are synthesized or by combining both procedures. By utilizing the gene of the present invention, namely by incorporating the same into a vector for use with a microorganism, for instance, and cultivating the transformant microorganism, the sphingosine 1-phosphate receptor protein can be expressed readily and in large quantities, and said protein can be isolated and provided. Since said protein has sphingosine 1-phosphate receptor activity, it is effective for various pharmacological purposes, and it is also useful, among others, in elucidating the pathogenesis, the pathologies or the like of various diseases. More specifically, the recombinant sphingosine 1-phosphate receptor protein obtained by utilizing the gene of the present invention can effectively be used, for example, in elucidating the mechanism of immunosuppression in living bodies, developing or screening out therapeutic agents for autoimmune diseases (e.g. rheumatism, SLE (systemic lupus erythematoses), LGL, etc.), searching for endogenous ligands and substrates to the novel protein and developing therapeutic agents therefor.

Similarly, the gene of the present invention can effectively be used, for example, in elucidating the mechanism of neurodegeneration in living bodies, developing or screening out therapeutic agents for neurodegenerative diseases (e.g. alzheimers, parkinson's and the like), searching for endogenous ligands and substrates to the novel protein and developing therapeutic agents therefor.

In the following, the gene of the present invention will be described in more detail. The gene of the present invention can be isolated by general genetic engineering techniques, for example, by selecting an appropriate clone from among a human fetal brain cDNA library (cDNA synthesized in the conventional manner from mRNA isolated and purified from total RNA obtained in turn from appropriate origin cells containing a gene coding for the sphingosine 1-phosphate receptor protein) using appropriate probes, such as for example those of SEQ ID 1 and SEQ ID 2, purifying said clone, and determining the base sequence thereof. In the above procedure, the origin cells may be any animal cells or tissues where the occurrence of sphingosine 1-phosphate receptor protein is known (see for example, the experiment producing the results shown in FIG. 6), or soluble fractions of cultured cells derived therefrom. This can be isolated and purified for the culture supernatant by various chromatographic processes.

In the practice of the present invention, it is also possible to use a part of the DNA fragment sequenced in the above manner as a probe, label this using a random prime DNA labeling kit (available from Takara Shuzo, Amersham, etc.) in

accordance with the random prime DNA labeling method (Feinberg, A. P., et al., Anal. Biochem., 137, 266-267 (1984)), for instance, and use the thus-obtained labeled probe in screening out the desired sphingosine 1-phosphate receptor protein gene.

Using the above-mentioned labeled probe, for instance, the desired DNA can be screened out by the plaque hybridization technique developed by Benton and Davis (Benton, W. and Davis, R., Science, 196, 383-394 (1977)).

The gene of the present invention as obtained in the above manner can be cloned in various plasmids in the conventional manner. For instance, after cleavage with an appropriate restriction enzyme and purification, the gene of the present invention can be inserted into a cloning vector (e.g. plasmid) cleaved with the same restriction enzyme and purified, at the cleavage site thereof, whereby a recombinant plasmid can be obtained. By introducing said recombinant into an appropriate host (e.g. *Escherichia coli*) for transformation, a restriction enzyme map of the clone containing said gene can be drawn using the transformant by a conventional known method, for example the method as described in Sambrook, J. Fritsch, E. F., and Maniatis. Molecular cloning. A laboratory Manual 2nd edition. Cold Spring Harbor laboratory Press. Cold Spring Harbor, N.Y. After digestion of the above clone with an appropriate restriction enzyme, the base sequence of said clone can be determined by the above-mentioned dideoxy method or the Maxam-Gilbert method, for instance. The base sequence determination mentioned above may also be readily performed using a commercially available kit or the like.

The thus-determined DNA base sequence of the sphingosine 1-phosphate receptor protein gene of the present invention and the corresponding amino acid sequence encoded thereby are as shown in the sequence listing under SEQ ID NO: 3 and SEQ ID NO: 4.

Using the above-mentioned gene (DNA) of the present invention, the recombinant sphingosine 1-phosphate receptor protein can be obtained by various known gene recombination techniques [cf. for example Science, 224, 1431 (1984); Biochem. Biophys. Res. Comm., 130, 692 (1985); Proc. Natl. Acad. Sci. USA, 80, 5990 (1983)]. Said sphingosine 1-phosphate receptor protein is produced, in more detail, by constructing a recombinant DNA allowing expression of the gene of the present invention in host cells, introducing this into host cells for transformation thereof, and cultivating the transformant strain. The host cells may be either eukaryotic or prokaryotic. As an expression vector for use with vertebrate cells, it is possible to use one containing a promoter generally located upstream of the gene to be expressed, an RNA splicing site, a polyadenylation site and a transcription termination sequence and so on. This may further have a replication origin, as necessary. Yeasts are often and generally used as eukaryotic microorganisms and, among them, yeasts belonging to the genus *Saccharomyces* are advantageously used. Usable as expression vectors for use with said yeasts and other eukaryotic microorganisms are pAM82 (A. Miyano-hara et al., Proc. Natl. Acad. Sci. USA, 80, 1-5 (1983)) containing a promoter for the acid phosphatase gene, and like vectors. *Escherichia coli* and *Bacillus subtilis* are generally and very often used as prokaryotic host cells. When these are used as hosts in the practice of the present invention, an expression plasmid is preferably used which is derived, for instance, from a plasmid vector capable of replication in said host microorganisms and provided with a promoter, the SD (Shine and Dalgarno) base sequence and further an initiation codon (e.g. ATG) necessary for the initiation of protein synthesis, upstream from the gene of the present invention so that

said gene can be expressed. As the host *Escherichia coli* mentioned above, the strain *Escherichia coli* K12 and the like are often used and, as the vector, pBR322 is generally and often used. However, the host and vector are not limited thereto, but other various known microbial strains and vectors can also be used. As regards the promoter, the tryptophan (trp) promoter, 1 pp promoter, lac promoter and P.sub.L promoter, for instance, can be used.

The thus-obtained desired recombinant DNA can be introduced into host cells for transformation thereof by various conventional methods. The transformant obtained can be cultivated in the conventional manner, leading to production and accumulation of the desired sphingosine 1-phosphate receptor protein encoded by the gene of the present invention. The medium to be used in said cultivation can adequately be selected, according to the host cells employed, from among various media in common use. When *Escherichia coli* or like cells are used as host cells, for instance, transformant cultivation can be conducted using LB medium, E medium, M9 medium, M63 medium or the like. To these media, there may be added, as necessary, generally known various carbon sources, nitrogen sources, inorganic salts, vitamins, nature-derived extracts, physiologically active substances, etc. The above-mentioned transformant cultivation can be carried out under conditions suited for the growth of the host cells. In the case of *Escherichia coli*, such conditions can be employed, for instance, as a pH of about 5 to 8, preferably 7 or thereabout, and a temperature of about 20 to 43.degree. C., preferably 37.degree. C. or thereabout. In the above manner, the transformant cells produce and accumulate intracellularly or secrete extracellularly the desired recombinant FK506 binding protein.

Said desired protein can be isolated and purified by various separation techniques utilizing its physical, chemical and other properties [cf. for example "Seikagaku (Biochemistry) Data Book II", pages 1175-1259, 1st edition, 1st printing, published Jun. 23, 1980 by Kabushiki Kaisha Tokyo Kagaku Dojin; Biochemistry, vol. 25, No. 25, 8274-8277 (1986); Eur. J. Biochem., 163, 313-321 (1987)]. As specific examples of said techniques, there may be mentioned conventional reconstitution treatment, treatment with a protein precipitating agent (salting out), centrifugation, osmotic pressure shock treatment, ultrasonic disruption, ultrafiltration, various liquid chromatographic processes such as molecular sieve chromatography (gel filtration), adsorption chromatography, ion exchange chromatography, affinity chromatography and high performance liquid chromatography (HPLC), dialysis, and combinations of these. In the above manner, the desired recombinant protein can be produced on an industrial scale with ease and with high efficiency.

In order to provide diagnostics for LGL leukemia, and provide therapeutic targets for drugs directed to mitigate the pathogenesis of LGL leukemia, microarray analysis is performed to identify differentially expressed genes. A large number of genes are identified that are differentially expressed in LGL leukemia compared to normal controls. One of the ESTs of approximately 300 base pairs is fully characterized herein. Initial Blast analysis shows 100% homology with Homo-sapiens full-length insert cDNA clone YY 85D04 (gb/AF 088014). No open reading frame within the full-length insert cDNA. Therefore, in order get the complete sequence of the gene, the LGL leukemia library is screened and also RT-PCR is performed using the total RNA isolated from different LGL leukemia patients. 15 positive clones are selected from library screening. All of them give partial sequences with the longest one being approximately 340 base pairs shorter (clone 6). BLAST search with htgs,

shows that clone 6 shows 100% homology with genomic sequence present in the chromosome 19. Primers are designed based on the genomic sequence information to obtain full-length sequence of the gene. By using these primers in the PCR with genomic DNA and RT-PCR with total RNA, the full-length gene, SEQ ID:4 is obtained. This gene belongs to the G-protein-coupled receptor super-family of integral membrane proteins. BLAST analysis of the complete gene reveals 85% homology with rat sphingosine 1-phosphate receptor edg-8 and nrg-1 (Im, D., et al., Characterization of a Novel sphingosine 1-Phosphate receptor, Edg-8. J. Biol. Chem. 275. 14281-14286 (2000); Glickman, M., et al., Molecular cloning, tissue-specific expression and chromosomal localization of a novel nerve growth factor regulated G-protein-coupled receptor, nrg-1. Mol. Cell. Neurosci. 14, 141-152 (1999)), shown in FIG. 4. It is interesting to note that this gene is present mainly in brain, spleen and PBMCs (FIG. 7), and it is over expressed in PBMC of LGL leukemia patients and is be involved in LGL leukemia cell survival or proliferation.

Material and Methods:

Isolation of Peripheral blood mononuclear cells (PBMC and RNA). PBMC are isolated from normal healthy individuals and from LGL leukemia patients. Trizole is obtained from GTBCO-BRL. EST (GenBank ID 1868427) is obtained Incyte Genomics. Oligotex mRNA mini-kit, plasmid isolation kits, gel extraction kits, and PCR reagents are purchased from Qiagen; RNA loading dye is from Sigma Chemical Co. The Prime-a-Gene labeling kit is from Promega Corp. (Madison, Wis.). Deoxycytidine 5' triphosphate dCTP a-32P (3,000 Ci/mmol) is from Dupont NEN (Boston, Mass.). Nytran membrane is obtained from Schleicher & Schuell, Inc., 10 optical Avenue, Keene, N. H. Nick translation columns are obtained from Pharmacia Chemical Co. The Topo-TA cloning kit is from Invitrogen.

PBMC are isolated from whole blood using Ficoll-Hypaque density gradient centrifugation. The PBMC cells are suspended in Trizole reagent (GIBCO-BRL, Rockville, Md.) and total RNA is immediately isolated according to the Oligotex mRNA mini-kit manufacturer's instructions and stored at -70° C. Poly A+ RNA is isolated from total RNA by using Oligo-Tex mini mRNA kit according to the manufacturer's recommendations. PBMCs are cultured in vitro and activated by Interleukin 2 and phytohemagglutinin (PHA) for 2 to 3 days. In a preferred embodiment, PBMC is cultured in vitro and activated by PHA, (Sigma Chemical Co. St. Louis, Mo.) (1 µg/ml, 2 days) and Interleukin-2 (IL-2) (100 U/ml, 10 days), Next, total RNA is isolated as described above.

Microarray probing and analysis is done by Incyte Genomics, (St. Louis, Mo.). Approximately 1 µg of Poly (A)+ RNA isolated from PBMCs of LGL leukemia and healthy individual is reverse transcribed to generate Cys3 and Cys 5 fluorescently labeled cDNA probes. In a preferred embodiment, more than 90% of PBMC from the LGL leukemia patient are leukemic LGL as indicated by CD 8+ staining. cDNA probes are competitively hybridized to a human UniGEM V cDNA microarray containing approximately 7075 immobilized cDNA fragments (4107 known genes and 2968 ESTs). Scanning and quantitation is performed by Incyte Genomics and balanced differential differentiation is given for all the genes. The balanced differential expression is calculated using the ratio between the P1 signal (intensity reading for probe 1) and the balanced P2 signal (intensity reading for probe 2 adjusted using the balanced coefficient). A balanced differential expression of 2.0 is considered indicative of up-regulation of a given gene.

Verification of clones: GEM cDNA clones are purchased from Incyte Genomics as individual bacterial stabs and streaked on LB/agar plates containing appropriate antibiotic(s). Individual colonies are picked and grown in LB medium. Plasmid DNA is isolated and sequenced in order to verify the correct identity of each clone.

Northern Blot analysis: Northern Blotting is done as described previously (Sambrook et al, 1998). Essentially, 10 ug of total RNA from each sample is denatured at 65° C. in a RNA loading buffer, electrophoresed in 1% agarose containing 2.2 M formaldehyde gel, and blotted onto a Nytran membrane. (Nytran membrane obtained from Schleicher & Schuell, Inc, Keene, N.H). The RNA is fixed to the membrane by UV cross-linking. cDNA is labeled with [³²P] (Prime-a-Gene labeling kit from Promega Corp. Madison, Wis., deoxycytidine 5' triphosphate (dCTP α-³²P, 3,000 Ci/mmol, Dupont NEN, Boston, Mass.) and purified by Nick columns (Amersham Pharmacia Biotech AB, Piscataway, N.J.). Hybridization and washings of the blots are performed as described by Engler-Blum, G., Meier, M., Frank, J., and Muller, G. A. Reduction of background in problems in non-radioactive Northern blot analysis enables higher sensitivity than 32P-based hybridizations. Anal. Biochem. 210, 235-244 (1993).

Library construction and screening. cDNA is synthesized from poly(A)⁺ RNA isolated from pooled PBMCs of multiple LGL leukemia patients using oligo dT primer. The cDNA is unidirectionally inserted the EcoRI/XhoI sites of Lambda ZAPII (Stratagene). cDNA library is screened using EST according to standard protocol (Sambrook et al., 1989). In a preferred embodiment, DNA libraries are plated at a density of 50,000 plaque-forming units per 150 mm plate. Following incubation for 8 h at 37° C., the plated phage are overlaid with nitrocellulose filters. After 1 min the filters are removed and the membranes are cross linked by Autocross linker. A [³²P] labeled cDNA fragment derived from an EST (GenBank accession No. N 47089) of interest is used to probe the filters. Hybridizations, washings, exposure of the membranes to films and then picking up the colony of interest are performed as outlined in the standard methodology (Sambrook et al., 1989). Secondary and tertiary screenings were also performed as outlined in standard methodology (Sambrook et al., 1989). After isolation of pure phage containing the gene of interest, mini-preparations or macro-preparation are made to isolate plasmid cDNA containing the gene of interest.

RT-PCR: To obtain the full-length sequence, 5' and 3' primers are designed based on the sequence information available in GenBank:

5' GC CGCGCCCAT GGAGTC 3' (SEQ.ID # 1)

is used as forward primer and

5' CTTTCTGTGTTCCCAAGC AGAAC GTCAAT 3' (SEQ.ID # 2)

is used as reverse primer. Total RNA from PBMC isolated from LGL leukemia patients and normal healthy individuals is used as a template for reverse transcriptase for making cDNA using either oligo(dT) primer or random hexamer primers. The PCR reaction mixture is heated to 95° C. for 2 min and then cycled 40 times at 95° C. for 30 sec, 60° C. for 45 sec, and 72° C. for 1.5 min. Finally, the reaction mixture is heated at 72° C. for 7 min and stored at 4° C. The reaction product is electrophoresed in 1% agarose gels. For direct PCR, all the conditions are the same as above except that

genomic DNA, isolated from PBMC, is used as a DNA template. PCR products are analyzed in 1% agarose gel and the bands are excised and cloned into a TOPO-TA cloning vector (Invitrogen) and sequenced. The insert is subcloned into EcoRI sites of mammalian expression vector pcDNA3.1 to produce pcDNA3S1P₅.

Cell culture and transfection. HEK293 cells are grown in Dulbecco's modified eagle's medium supplemented with 10% fetal bovine serum. The cells are transiently transfected with a plasmid encoding HA-tagged Erk2 (HA-Erk2) and either pcDNA 3 S1P₅ or pcDNA 3.1. Transfection is achieved by incubating the cells in 60 mm plates with plasmid/Lipofectamine complexes (2.1 μg total DNA/12 μl Lipofectamine) in serum-free medium for 5 hours. The DNA complexes are removed from the medium and the cells are starved overnight in serum-free medium and then used for experimentation.

Erk2 Kinase Assay. The serum-starved transiently transfected HEK293 cells are treated for 5 min preferably with either 1 μM sphingosine-1-phosphate (S1P) or with 1 μM lysophosphatidic acid (LPA). The cells are lysed in buffer containing 50 mM Tris-HCl pH 7.5, 150 mM NaCl, 1 mM EDTA, 1 mM EGTA, 1 mM DTT, 1% Triton X-100, 25 mM NaF, 5 mM sodium pyrophosphate, 20 mM p-nitrophenyl phosphate, 2 μg/mL leupeptin, and 100 μg/mL phenylmethylsulfonyl fluoride. HA-Erk2 is immunoprecipitated with the monoclonal antibody HA.11 (Convance, Richmond, Calif.). Half of the immunoprecipitate is used to determine Erk 2 activity and the other half is used for measuring Erk2 protein expression. For the kinase assay, immune complexes are incubated for 10 min at 30° C. in 40 μl of buffer containing 20 mM Hepes, pH 7.5, 10 mM MgCl₂, 1 mM dithiothreitol, 10 mM p-nitrophenyl phosphate, 40 μM ATP and 0.375 mg/mL myelin basic protein and 10 μCi of [γ-³²P] ATP (3000 Ci/mmol). The reaction is terminated with SDS-containing gel-loading buffer and the reaction mixtures are analyzed on 11% SDS-polyacrylamide gels. The gels are processed by autoradiography. The bands on the gels are quantitated with a Phosphorimager. Erk2 protein in the immunoprecipitate is determined by immunoblotting with a polyclonal antibody to Erk2.

EXAMPLES

Referring now to FIG. 1, approximately 50 genes are up-regulated in LGL leukemia, with balanced differential expression of between about 7.8 and about 2.0. In addition, one EST is particularly noteworthy that is up-regulated in LGL leukemia with balanced differential expression of 3.0 (GenBank Accession number N47089). A clone containing this EST is sequenced. The total length of the EST is approximately 300 base pairs. A search using Blast shows 100% homology with another EST (GenBank Accession No. AF088014) named as *homo sapiens* full length insert cDNA clone YY85D04. No other information regarding this EST is found in the literature. Northern blot analysis confirms that a gene related to EST (GenBank ID No. N47098) is upregulated in majority of LGL leukemia patients.

Using the microarray screening method, one LGL leukemia patient is compared with one normal healthy individual. To show the same pattern in a larger sample of patents, Northern blot analysis is performed. Total RNAs, isolated from the PBMC of normal healthy individuals and LGL leukemia patients, are used in Northern blots. Initially, a 300 base pair cDNA fragment is used as a probe in initial experiments. Up-regulation of EST is observed in all the LGL leukemia patients when compared to the normal healthy individuals.

This confirms the microarray results regarding EST expression. The probe hybridizes to a 2.2 kb transcript in the Northern Blots. (FIG.-2).

An LGL leukemia library is constructed from the mRNA isolated from the pooled PBMCs of the seven LGL leukemia patients. This library is screened to obtain full-length sequence of the gene. Approximately 15 positive clones are selected and the larger clones are sequenced. The largest clone is 1500 bp in length. Analysis using Blast indicates that this gene has 85% homology with Rat edg-8 (Im et al, 2000). All of the clones are missing 5' end of the gene. Blast search with htgs show 99% homology with the sequence present in chromosome 19. Based on the sequence information, primers are designed from the 5' end and from 3' end of the open reading frame of the gene. Three different products (1.5, 1.6, and 1.2 bp in length) are obtained using RT-PCR. These products are subjected to gel electrophoresis and bands are excised, cloned into TOPO-TA cloning vectors and sequenced. The largest PCR product contains the entire open reading frame (FIG. 3). The deduced amino acid sequence shows 85% homology with complete sequence of rat sphingosine 1-phosphate receptor edg-8 and nrg-1. (FIG. 4). Shorter bands are also identified. The shorter bands are excised, cloned, and sequenced. These clones are splice variants of sphingosine 1-phosphate receptor with deletions. They are herein termed "sphingosine 1-phosphate receptor-1" and "sphingosine 1-phosphate receptor-2" (FIGS. 5 & 6).

Expression of sphingosine 1-phosphate receptor is examined in different normal tissues by Northern blot analysis. It is found that *sppr* is expressed in several tissues such as brain, spleen and PBMCs. (FIG. 7). Only trace amounts are detected in Jukat and CEM cell lines (data not shown).

To obtain a full-length sequence of the gene, an LGL leukemic cDNA library is constructed and screened using the EST probe. Approximately 15 positive clones are selected and larger clones are sequenced. The BLAST search of the largest clone (1500 bp) indicates that this gene has strong homology with Rat edg-8/Nrg-1. However, all of the clones are missing the 5' end of the gene when compared to the rat gene. A BLAST search with the human genome shows 99% homology with a sequence present on chromosome 19. Based on this sequence information, primers are designed from the 5' and 3' ends of the open reading frame of the gene.

Three different RT-PCR products (1.5, 1.6, and 1.2 bp) are obtained. These products are subjected to gel electrophoresis. The resulting bands are excised and cloned into TOPO-TA cloning vectors and then sequenced. The largest PCR product contains a complete open reading frame. The nucleotide sequence and the deduced amino acids are shown in FIG. 8. The gene is designated as SIP₅ (see below). The nucleotide sequence shows very strong homology with G-protein coupled receptors, especially with the endothelial differentiation genes (EDGs). When the deduced amino acid sequence of the full-length sequence is aligned with other members of the family using the CLUSTALW (multi sequence alignment) program, it is approximately 26 to 44% identical and 58 to 72% similar with EDGs at amino acid level (Table 1). In addition, it shows 86% identity and 96% similarity with rat edg-8 or rat nrg-1 at amino acid level. (FIG. 9, Table I). Transient transfection of HEK293 cells with this gene results in activation of Erk2 activity in response to sphingosine-1-phosphate but not LPA, confirming that it is a sphingosine-1-phosphate receptor (FIG. 10). Therefore, this gene is named SIP₅.

Samples from 30 LGL leukemia patients are tested for the presence of SIP₅ transcript by Northern blot analysis using full-length gene as a probe. Constitutive expression of SIP₅

transcripts is found in 24 samples (FIG. 11). In comparison SIP₅ transcripts are expressed at only trace levels in normal PBMC (N=12). After activation of normal PBMC the expression of SIP₅ is reduced to undetectable levels (FIG. 12). Additionally, expression of two smaller bands is detected in samples from leukemic LGL by RT-PCR. Human SIP₅ transcripts are expressed mainly in normal brain, spleen, and PBMC and in trace amounts in lung, kidney and liver (FIG. 13). Whereas expression of Edg-8 is observed only in brain and spleen of rat when Northern Blots are probed. Several cell lines are examined for the presence of SIP₅ transcript. Trace amounts of SIP₅ transcripts are identified in CEM and Jurkat cells (data not shown). All other cell lines tested are negative for SIP₅ transcript including MT2 (HTLV-I infected cell line) and MO-T (HTLV-II infected cell line), Moe7 (megakaryoblastic leukemic cell line) and U293 (human embryonic kidney cells).

TABLE 1

Identity and similarity between SIP₅ and other members of the Edgs. The deduced amino acid sequence of SIP₅ is aligned with the amino acid sequences of various members of Edgs. using the CLUSTALW program. Except for Edg 8 and nrg-1, all other sequences are from human. All the sequence information is obtained from GenBank.

Name of the gene	% Identity	% Similarity
hSIP5	100	100
rEdg-8*	87	96
rNrg-1	86	98
h Edg-1*	44	72
hEdg-5*	41	66
h Edg-3*	40	70
h Edg-6*	39	67
h Edg-2 [†]	35	67
h Edg-4 [†]	30	60
hEdg-7 [†]	26	58

* = Sphingosine 1-phosphate receptors

[†] = Lysophosphatidic acid receptors

Discussion

Leukemic LGL are resistant to Fas-induced apoptosis, in spite of over-expression of Fas and Fas-ligand (FasL) implying that the accumulation of circulating LGL can be due to dysregulation of apoptosis. The accumulation of circulating LGL in leukemic patients can also be due to clonal proliferation of LGL. In order to understand the molecular mechanisms involved in pathogenesis of LGL leukemia, microarray techniques are used to identify differentially expressed genes. Approximately 50 genes are identified that are up-regulated and 10 genes that are down regulated. Several ESTs are also identified which show differential expression. As a systematic study, one of the ESTs that is up-regulated in LGL Leukemia is characterized. The full-length gene is obtained by screening the LGL leukemia library and performing RT-PCR, which is 85% identical to the rat Sphingosine-1 Phosphate receptor. This gene belongs to G-protein coupled receptor super family and can act as a sphingosine-1-phosphate receptor. Several splice variants in LGL leukemia patients are also identified, and are named Sphingosine 1-phosphate receptor 1 and Sphingosine 1-Phosphate receptor 2. The deduced amino acid sequence of Sphingosine 1-Phosphate receptor with rat edg-8 or nrg shows 85% homology. It has seven transmembrane domains, which is a characteristic of GTP-coupled receptors. Thus, the Sphingosine-1 Phosphate is involved in the signal transduction from the sphingosine 1-Phosphate in human.

Although the gene has lot of homology with other members of edg family, it is preferably named sphingosine-1-

phosphate receptor (S1P₅) because it is mainly present in lymphocytes, brain and spleen, but not in endothelial cells.

Lysophosphatidic acid (LPA) and sphingosine 1-phosphate (S1P) mediate T cell function. Both LPA and S1P signaling pathways are implicated in cell proliferation, suppression of apoptosis, enhancement of cellular survival and T-lymphoma cell invasion. Although it has been suggested that S1P can act as an intracellular mediator, it has also been suggested that S1P acts as an extracellular ligand for cell surface receptors. Indeed several such receptors have been identified in a wide variety of tissues. For example, receptors Edg-1, -3, -5, -6 and -8, are specific for S1P, whereas Edg-2, -4, and -7 are LPA specific. In normal lymphocytes, there is differential constitutive expression of receptors for LPA and S1P. CD4⁺ cells express predominantly Edg-4, while CD8⁺ cells appeared to lack receptors for LPA and S1P as only traces of Edg-2 and Edg-5 are detected. Human T cell tumors express many Edgs for both LPA and S1P.

Rat edg-8/nrg-1 is shown to be a sphingosine-1-phosphate receptor based on specific binding of radio-labeled S1P to cell membranes, inhibition of forskolin-induced cAMP accumulation, increased GTP binding ability and calcium mobilization studies. Even though these properties are adequate to classify edg-8/nrg-1 as a sphingosine-1-phosphate receptor, it seems surprising that this one is different from other members of the human sphingosine-1-phosphate receptor family. For example, activation of EDG-1, -3, -5 and -6 by S1P leads to activation of Erk1/2 and induction of cell proliferation. In contrast S1P inhibited serum-induced activation of Erk1/2 and also inhibits the cell proliferation in CHO cells expressing EDG-8. The reasons for these differences are not known and might be due to species variation. As shown herein, S1P

activates Erk2 in transiently transfected HEK293 cells while lysophosphatidic acid does not, suggesting that S1P₅ is a sphingosine-1-phosphate receptor and participates in sphingosine 1-phosphate mediated signal transduction. A computational model of the Edg-1 receptor predicts that Glu¹²¹ is essential for interaction with S1P [21]. The S1P receptors Edg-1, -3, -5 and -8 as well as S1P₅ share such an anionic residue.

Leukemic LGL are antigen driven CTL that survive in vivo, at least in part, because of defective apoptosis. For example, leukemic LGL express both Fas and Fas-ligand, but are resistant to Fas mediated death. It is noteworthy that S1P₅ gene transcripts are down regulated after activation of normal T cells. Leukemic cells are activated T cells. Based upon the results disclosed herein, constitutive expression of S1P₅ transcripts represents dysregulated expression. This dysregulated expression of S1P₅ may participate in protection of leukemic LGL from apoptosis.

Note: The full-length sequence was deposited in GenBank (Accession No. AF331840) on Dec. 22, 2000.

Throughout this application, various publications, including United States patents, have been referred to. The disclosures of these publications and patents in their entireties are hereby incorporated by reference into this application to more fully describe the state of the art to which this invention pertains.

While the invention has been described in terms of various preferred embodiments, those skilled in the art will recognize that various modifications, substitutions, omissions, and changes may be made without departing from the spirit of the present invention. Accordingly, it is intended that the scope of the present invention be limited solely by the scope of the following claims.

SEQUENCE LISTING

<160> NUMBER OF SEQ ID NOS: 19

<210> SEQ ID NO 1
 <211> LENGTH: 17
 <212> TYPE: DNA
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: Probe (see p. 8 of specification)

<400> SEQUENCE: 1

gcgcggccca tggagtc

17

<210> SEQ ID NO 2
 <211> LENGTH: 30
 <212> TYPE: DNA
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: Probe (see p. 8 of specification)

<400> SEQUENCE: 2

cttttctgtg ttcccaagca gaacgtcaat

30

<210> SEQ ID NO 3
 <211> LENGTH: 398
 <212> TYPE: PRT
 <213> ORGANISM: Homo sapiens
 <220> FEATURE:
 <221> NAME/KEY: MISC_FEATURE
 <223> OTHER INFORMATION: Human sphingosine 1-Phosphate receptor (SPPR) amino acid sequence (Figure 3)

-continued

<400> SEQUENCE: 3

Met Glu Ser Gly Leu Leu Arg Pro Ala Pro Val Ser Glu Val Ile Val
 1 5 10 15
 Leu His Tyr Asn Tyr Thr Gly Lys Leu Arg Gly Ala Arg Tyr Gln Pro
 20 25 30
 Gly Ala Gly Leu Arg Ala Asp Ala Val Val Cys Leu Ala Val Cys Ala
 35 40 45
 Phe Ile Val Leu Glu Asn Leu Ala Val Leu Leu Val Leu Gly Arg His
 50 55 60
 Pro Arg Phe His Ala Pro Met Phe Leu Leu Leu Gly Ser Leu Thr Leu
 65 70 75 80
 Ser Asp Leu Leu Ala Gly Ala Ala Tyr Ala Ala Asn Ile Leu Leu Ser
 85 90 95
 Gly Pro Leu Thr Leu Lys Leu Ser Pro Ala Leu Trp Phe Ala Arg Glu
 100 105 110
 Gly Gly Val Phe Val Ala Leu Thr Ala Ser Val Leu Ser Leu Leu Ala
 115 120 125
 Ile Ala Leu Glu Arg Ser Leu Thr Met Ala Arg Arg Gly Pro Ala Pro
 130 135 140
 Val Ser Ser Arg Gly Arg Thr Leu Ala Met Ala Ala Ala Trp Gly
 145 150 155 160
 Val Ser Leu Leu Leu Gly Leu Leu Pro Ala Leu Gly Trp Asn Cys Leu
 165 170 175
 Gly Arg Leu Asp Ala Cys Ser Thr Val Leu Pro Leu Tyr Ala Lys Ala
 180 185 190
 Tyr Val Leu Phe Cys Val Leu Ala Phe Val Gly Ile Leu Ala Ala Ile
 195 200 205
 Cys Ala Leu Tyr Ala Arg Ile Tyr Cys Gln Val Arg Ala Asn Ala Arg
 210 215 220
 Arg Leu Pro Ala Arg Pro Gly Thr Ala Gly Thr Thr Ser Thr Arg Ala
 225 230 235 240
 Arg Arg Lys Pro Arg Ser Leu Ala Leu Leu Arg Thr Leu Ser Val Val
 245 250 255
 Leu Leu Ala Phe Val Ala Cys Trp Gly Pro Leu Phe Leu Leu Leu Leu
 260 265 270
 Leu Asp Val Ala Cys Pro Ala Arg Thr Cys Pro Val Leu Leu Gln Ala
 275 280 285
 Asp Pro Phe Leu Gly Leu Ala Met Ala Asn Ser Leu Leu Asn Pro Ile
 290 295 300
 Ile Tyr Thr Leu Thr Asn Arg Asp Leu Arg His Ala Leu Leu Arg Leu
 305 310 315 320
 Val Cys Cys Gly Arg His Ser Cys Gly Arg Asp Pro Ser Gly Ser Gln
 325 330 335
 Gln Ser Ala Ser Ala Ala Glu Ala Ser Gly Gly Leu Arg Arg Cys Leu
 340 345 350
 Pro Pro Gly Leu Asp Gly Ser Phe Ser Gly Ser Glu Arg Ser Ser Pro
 355 360 365
 Gln Arg Asp Gly Leu Asp Thr Ser Gly Ser Thr Gly Ser Pro Gly Ala
 370 375 380
 Pro Thr Ala Ala Arg Thr Leu Val Ser Glu Pro Ala Ala Asp
 385 390 395

<210> SEQ ID NO 4

<211> LENGTH: 2336

-continued

```

<212> TYPE: DNA
<213> ORGANISM: Homo sapiens
<220> FEATURE:
<221> NAME/KEY: MISC_FEATURE
<223> OTHER INFORMATION: Human sphingosine 1-Phosphate receptor (SPPR)
      cDNA sequence (Figure 3)

<400> SEQUENCE: 4

gcgcgccca tggagtcggg gctgctcggg ccggcgccgg tgagcgaggt catcgctctg    60
cattacaact acaccggcaa gctccgcggt gcgcgctacc agccgggtgc cggcctgcgc    120
gccgacgceg tgggtgtgct gggcggtgtc gccttcctcg tgctagagaa tctagccgtg    180
ttgttggtgc tcggacgcca cccgcgcttc cacgctccca tgttctctct cctgggcagc    240
ctcacgttgt cggatctgct ggcaggcgcc gcctacgccc ccaacatcct actgtcgggg    300
ccgctcacgc tgaactgtc ccccgcgctc tggttcgcac gggagggagg cgtcttcgtg    360
gcaactcactg cgtccgtgct gagcctcctg gccatcgcgc tggagcgag cctcaccatg    420
gcgcgcaggg gcccgcgccc cgtctccagt cggggcgca cgctggcgat ggcagccgcg    480
gcctggggcg tgtcgtgct cctcgggctc ctgccagcgc tgggctgaa ttgcctgggt    540
cgcttgagc cttgtccac tgtcttgccc ctctacgcca aggcctacgt gctcttctgc    600
gtgctcgct tcgtgggcat cctggccgcg atctgtgca tctacgcgcg catctactgc    660
caggtaacgc ccaacgcgcg gcgctgccc gcacggccc ggactgcggg gaccacctcg    720
accggggcgc gtcgcaagc gcgctcctg gccttctgc gcaacgctcag cgtggtgctc    780
ctggcctttg tggcatgtt gggccccctc ttctgctgc tgttgcctga cgtggcgctg    840
ccggcgcgca cctgtcctgt actcctgcag gccgatccct tctgggact ggccatggcc    900
aactcacttc tgaacccat catctacacg ctcaccaacc ggcactgctg ccacgcgctc    960
ctgcgcctgg tetgtgcgg acgccaactc tcgcgagag acccgagtgg ctcccagcag   1020
tcggcgagcg cggctgaggc ttccgggggc ctgcgcccgt gcctgcccc gggccttgat   1080
gggagcttca gggctcggg gcgctcctcg ccccagcgcg acgggctgga caccagcggc   1140
tccacaggca gccccggtgc acccacagcc gcccgactc tggatcaga accggtgca   1200
gactgacacc ctcgccccac gactgtcttc ccaagttta cagacttgtt ctttttacct   1260
aaaggaattt gtaggaaatg cagccaaagg tgcagtcgga aaagatgcag gggaaatgta   1320
tttatgcagc gacacccac aatgtgaaca aacagacaaa aaatctgtgc cctcgtggaa   1380
ttgacgttct gcttgggaac acagaaaaga actcgggtgat gaaataatgg agatgattcc   1440
agtgacaaac gacagagatg gtgatggtg tcaggaaga cctctctgca gaggtagtga   1500
cttgtgatgt gagctgagac ctctgtcctg ggaagaccaa aagaaaagca tttcaggatg   1560
agggaatggc atgcgcaaag gccctgaggc tgaatgtgc coattgttct taagaaatgc   1620
agcgatgctg gttgcctgg agcagggacg gagggggaga atgggaggag acaaggagct   1680
gaaggagtag tcccgaagg accttggggg tgatatagag gacttcgctt ttgctctgag   1740
tgaggtggga gccatagaag cttctaagca gaagaggac ttgcctaata tcaggtgatc   1800
acaggtgtct tgtggcctcc atgggaggtt gaaaaccaca gaaggtgaag gggggctgca   1860
ctgagccaca ggaacaatg tggagattcc agctaagccc agaccccgtg gattctagat   1920
agattttaga ggcagcagac agaattactg aggaattgag tgtaagagtg gaataaagtt   1980
atcaaggaca atgccaaggg tggggcacc ccaaatgtga ctttgggaga ctcagccaaa   2040
tcctatctgg taataaaatt tcttttttat tttcttttct tttctttctt tctttctttc   2100
tttttttttt tttgagttgg gatcttgtgc tctgtcaacc aggetggagt gcaatgggca   2160

```

-continued

```

caattatagc tcaactgcagc ctggaactcc tgggatcaag cctggagttc ctgcttcagc 2220
ctccttagta gctgggacta caggcatgca ccaccatgcc cagttaataa aattttctca 2280
aatgcaaaaa aaaaaaaaaa aaaaaactcg agggggggcc cggtacccaa ttcgcc 2336

```

```

<210> SEQ ID NO 5
<211> LENGTH: 400
<212> TYPE: PRT
<213> ORGANISM: Rattus norvegicus
<220> FEATURE:
<221> NAME/KEY: MISC_FEATURE
<223> OTHER INFORMATION: Nrg-1 rat genes (Figure 4)

```

```

<400> SEQUENCE: 5

```

```

Met Glu Ser Gly Leu Leu Arg Pro Ala Pro Val Ser Glu Val Ile Val
1          5          10          15
Leu His Tyr Asn Tyr Thr Gly Lys Leu Arg Gly Ala Arg Tyr Gln Pro
                20          25          30
Gly Ala Gly Leu Arg Ala Asp Ala Ala Val Cys Leu Ala Val Cys Ala
          35          40          45
Phe Ile Val Leu Glu Asn Leu Ala Val Leu Leu Val Leu Gly Arg His
          50          55          60
Pro Arg Phe His Ala Pro Met Phe Leu Leu Leu Gly Ser Leu Thr Leu
65          70          75          80
Ser Asp Leu Leu Ala Gly Ala Ala Tyr Ala Thr Asn Ile Leu Leu Ser
          85          90          95
Gly Pro Leu Thr Leu Arg Leu Ser Pro Ala Leu Trp Phe Ala Arg Glu
          100          105          110
Gly Gly Val Phe Val Ala Leu Ala Ala Ser Val Leu Ser Leu Leu Ala
          115          120          125
Ile Ala Ile Glu Arg His Leu Thr Met Ala Arg Arg Gly Pro Ala Pro
          130          135          140
Ala Ala Ser Arg Ala Arg Thr Leu Ala Met Ala Val Ala Ala Trp Gly
145          150          155          160
Leu Leu Leu Thr Leu Gly Leu Leu Pro Ala Leu Gly Trp Asn Cys Leu
          165          170          175
Gly Arg Leu Glu Ala Cys Ser Thr Val Leu Pro Val Tyr Ala Lys Ala
          180          185          190
Tyr Val Leu Phe Cys Val Leu Ala Phe Leu Gly Ile Leu Ala Ala Ile
          195          200          205
Cys Ala Leu Tyr Ala Arg Ile Tyr Cys Gln Val Arg Ala Asn Ala Arg
210          215          220
Arg Leu Arg Ala Gly Pro Gly Ser Arg Arg Ala Thr Ser Ser Ser Arg
225          230          235          240
Ser Arg His Thr Pro Arg Ser Leu Ala Leu Leu Arg Thr Leu Ser Val
          245          250          255
Val Leu Leu Ala Phe Val Ala Cys Trp Gly Pro Leu Phe Leu Leu Leu
          260          265          270
Leu Leu Asp Val Ala Cys Pro Ala Arg Ala Cys Pro Val Leu Leu Gln
          275          280          285
Ala Asp Pro Phe Leu Gly Leu Ala Met Ala Asn Ser Leu Leu Asn Pro
290          295          300
Ile Ile Tyr Thr Phe Thr Asn Arg Asp Leu Arg His Ala Leu Leu Arg
305          310          315          320
Leu Leu Cys Cys Gly Arg Gly Pro Cys Asn Gln Asp Ser Ser Asn Ser
          325          330          335

```

-continued

Leu Gln Arg Ser Pro Ser Ala Val Gly Pro Ser Gly Gly Gly Leu Arg
 340 345 350

Arg Cys Leu Pro Pro Thr Leu Asp Arg Ser Ser Ser Pro Ser Glu His
 355 360 365

Ser Cys Pro Gln Arg Asp Gly Met Asp Thr Ser Cys Ser Thr Gly Ser
 370 375 380

Pro Gly Ala Ala Thr Ala Asn Arg Thr Leu Val Pro Asp Ala Thr Asp
 385 390 395 400

<210> SEQ ID NO 6
 <211> LENGTH: 400
 <212> TYPE: PRT
 <213> ORGANISM: Rattus norvegicus
 <220> FEATURE:
 <221> NAME/KEY: MISC_FEATURE
 <223> OTHER INFORMATION: EDG-8 rat genes (Figure 4)

<400> SEQUENCE: 6

Met Glu Ser Gly Leu Leu Arg Pro Ala Pro Val Ser Glu Val Ile Val
 1 5 10 15

Leu His Tyr Asn Tyr Thr Gly Lys Leu Arg Gly Ala Arg Tyr Gln Pro
 20 25 30

Gly Ala Gly Leu Arg Ala Asp Ala Ala Val Cys Leu Ala Val Cys Ala
 35 40 45

Phe Ile Val Leu Glu Asn Leu Ala Val Leu Leu Val Leu Gly Arg His
 50 55 60

Pro Arg Phe His Ala Pro Met Phe Leu Leu Leu Gly Ser Leu Thr Leu
 65 70 75 80

Ser Asp Leu Leu Ala Gly Ala Ala Tyr Ala Thr Asn Ile Leu Leu Ser
 85 90 95

Gly Pro Leu Thr Leu Arg Leu Ser Pro Ala Leu Trp Phe Ala Arg Glu
 100 105 110

Gly Gly Val Phe Val Ala Leu Ala Ala Ser Val Leu Ser Leu Leu Ala
 115 120 125

Ile Ala Leu Glu Arg His Leu Thr Met Ala Arg Arg Gly Pro Ala Pro
 130 135 140

Ala Ala Ser Arg Ala Arg Thr Leu Ala Met Ala Val Ala Ala Trp Gly
 145 150 155 160

Leu Ser Leu Leu Leu Gly Leu Leu Pro Ala Leu Gly Trp Asn Cys Leu
 165 170 175

Gly Arg Leu Glu Ala Cys Ser Thr Val Leu Pro Leu Tyr Ala Lys Ala
 180 185 190

Tyr Val Leu Phe Cys Val Leu Ala Phe Leu Gly Ile Leu Ala Ala Ile
 195 200 205

Cys Ala Leu Tyr Ala Arg Ile Tyr Cys Gln Val Arg Ala Asn Ala Arg
 210 215 220

Arg Leu Arg Ala Gly Pro Gly Ser Arg Arg Ala Thr Ser Ser Ser Arg
 225 230 235 240

Ser Arg His Thr Pro Arg Ser Leu Ala Leu Leu Arg Thr Leu Ser Val
 245 250 255

Val Leu Leu Ala Phe Val Ala Cys Trp Gly Pro Leu Phe Leu Leu Leu
 260 265 270

Leu Leu Asp Val Ala Cys Pro Ala Arg Ala Cys Pro Val Leu Leu Gln
 275 280 285

Ala Asp Pro Phe Leu Gly Leu Ala Met Ala Asn Ser Leu Leu Asn Pro
 290 295 300

-continued

```

Ile Ile Tyr Thr Phe Thr Asn Arg Asp Leu Arg His Ala Leu Leu Arg
305                310                315                320

Leu Leu Cys Cys Gly Arg Gly Pro Cys Asn Gln Asp Ser Ser Asn Ser
                325                330                335

Leu Gln Arg Ser Pro Ser Ala Val Gly Pro Ser Gly Gly Gly Leu Arg
                340                345                350

Arg Cys Leu Pro Pro Thr Leu Asp Arg Ser Ser Ser Pro Ser Glu His
                355                360                365

Ser Cys Pro Gln Arg Asp Gly Met Asp Thr Ser Cys Ser Thr Gly Ser
                370                375                380

Pro Gly Ala Ala Thr Ala Asn Arg Thr Leu Val Pro Asp Ala Thr Asp
385                390                395                400

```

```

<210> SEQ ID NO 7
<211> LENGTH: 398
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens
<220> FEATURE:
<221> NAME/KEY: MISC_FEATURE
<223> OTHER INFORMATION: SPPR (Figure 4)

```

```

<400> SEQUENCE: 7

```

```

Met Glu Ser Gly Leu Leu Arg Pro Ala Pro Val Ser Glu Val Ile Val
1                5                10                15

Leu His Tyr Asn Tyr Thr Gly Lys Leu Arg Gly Ala Arg Tyr Gln Pro
                20                25                30

Gly Ala Gly Leu Arg Ala Asp Ala Val Val Cys Leu Ala Val Cys Ala
                35                40                45

Phe Ile Val Leu Glu Asn Leu Ala Val Leu Leu Val Leu Gly Arg His
50                55                60

Pro Arg Phe His Ala Pro Met Phe Leu Leu Leu Gly Ser Leu Thr Leu
65                70                75                80

Ser Asp Leu Leu Ala Gly Ala Ala Tyr Ala Ala Asn Ile Leu Leu Ser
                85                90                95

Gly Pro Leu Thr Leu Lys Leu Ser Pro Ala Leu Trp Phe Ala Arg Glu
100                105                110

Gly Gly Val Phe Val Ala Leu Thr Ala Ser Val Leu Ser Leu Leu Ala
115                120                125

Ile Ala Leu Glu Arg Ser Leu Thr Met Ala Arg Arg Gly Pro Ala Pro
130                135                140

Val Ser Ser Arg Gly Arg Thr Leu Ala Met Ala Ala Ala Ala Trp Gly
145                150                155                160

Val Ser Leu Leu Leu Gly Leu Leu Pro Ala Leu Gly Trp Asn Cys Leu
165                170                175

Gly Arg Leu Asp Ala Cys Ser Thr Val Leu Pro Leu Tyr Ala Lys Ala
180                185                190

Tyr Val Leu Phe Cys Val Leu Ala Phe Val Gly Ile Leu Ala Ala Ile
195                200                205

Cys Ala Leu Tyr Ala Arg Ile Tyr Cys Gln Val Arg Ala Asn Ala Arg
210                215                220

Arg Leu Pro Ala Arg Pro Gly Thr Ala Gly Thr Thr Ser Thr Arg Ala
225                230                235                240

Arg Arg Lys Pro Arg Ser Leu Ala Leu Leu Arg Thr Leu Ser Val Val
245                250                255

Leu Leu Ala Phe Val Ala Cys Trp Gly Pro Leu Phe Leu Leu Leu Leu
260                265                270

```

-continued

Leu Asp Val Ala Cys Pro Ala Arg Thr Cys Pro Val Leu Leu Gln Ala
 275 280 285
 Asp Pro Phe Leu Gly Leu Ala Met Ala Asn Ser Leu Leu Asn Pro Ile
 290 295 300
 Ile Tyr Thr Leu Thr Asn Arg Asp Leu Arg His Ala Leu Leu Arg Leu
 305 310 315 320
 Val Cys Cys Gly Arg His Ser Cys Gly Arg Asp Pro Ser Gly Ser Gln
 325 330 335
 Gln Ser Ala Ser Ala Ala Glu Ala Ser Gly Gly Leu Arg Arg Cys Leu
 340 345 350
 Pro Pro Gly Leu Asp Gly Ser Phe Ser Gly Ser Glu Arg Ser Ser Pro
 355 360 365
 Gln Arg Asp Gly Leu Asp Thr Ser Gly Ser Thr Gly Ser Pro Gly Ala
 370 375 380
 Pro Thr Ala Ala Arg Thr Leu Val Ser Glu Pro Ala Ala Asp
 385 390 395

<210> SEQ ID NO 8
 <211> LENGTH: 254
 <212> TYPE: PRT
 <213> ORGANISM: Homo sapiens
 <220> FEATURE:
 <221> NAME/KEY: MISC_FEATURE
 <223> OTHER INFORMATION: Sphingosine-1-phosphate receptor.1 (Figure 5)

<400> SEQUENCE: 8

Met Glu Ser Gly Leu Leu Arg Pro Ala Pro Val Ser Glu Val Ile Val
 1 5 10 15
 Leu His Tyr Asn Tyr Thr Gly Lys Leu Arg Gly Ala Arg Tyr Gln Pro
 20 25 30
 Gly Ala Gly Leu Arg Ala Asp Ala Val Val Cys Leu Ala Val Cys Ala
 35 40 45
 Phe Ile Val Leu Glu Asn Leu Ala Val Leu Leu Val Leu Gly Arg His
 50 55 60
 Pro Arg Phe His Ala Pro Met Phe Leu Leu Leu Gly Ser Leu Thr Leu
 65 70 75 80
 Ser Val Pro Ala Arg Pro Gly Thr Ala Gly Thr Thr Ser Thr Arg Ala
 85 90 95
 Arg Arg Lys Pro Arg Ser Leu Ala Leu Leu Arg Thr Leu Ser Val Val
 100 105 110
 Leu Leu Ala Phe Val Ala Cys Trp Gly Pro Leu Phe Leu Leu Leu Leu
 115 120 125
 Leu Asp Val Ala Cys Pro Ala Arg Thr Cys Pro Val Leu Leu Gln Ala
 130 135 140
 Asp Pro Phe Leu Gly Leu Ala Met Ala Asn Ser Leu Leu Asn Pro Ile
 145 150 155 160
 Ile Tyr Thr Leu Thr Asn Arg Asp Leu Arg His Ala Leu Leu Arg Leu
 165 170 175
 Val Cys Cys Gly Arg His Ser Cys Gly Arg Asp Pro Ser Gly Ser Gln
 180 185 190
 Gln Ser Ala Ser Ala Ala Glu Ala Ser Gly Gly Leu Arg Arg Cys Leu
 195 200 205
 Pro Pro Gly Leu Asp Gly Ser Phe Ser Gly Ser Glu Arg Ser Ser Pro
 210 215 220
 Gln Arg Asp Gly Leu Asp Thr Ser Gly Ser Thr Gly Ser Pro Gly Ala
 225 230 235 240

-continued

Pro Thr Ala Ala Arg Thr Leu Val Ser Glu Pro Ala Ala Asp
 245 250

```

<210> SEQ ID NO 9
<211> LENGTH: 1698
<212> TYPE: DNA
<213> ORGANISM: Homo sapiens
<220> FEATURE:
<221> NAME/KEY: misc_feature
<223> OTHER INFORMATION: Sphingosine-1-phosphate receptor.1 (Figure 5)

<400> SEQUENCE: 9

cgcgcgcccc atggagtcgg ggctgctgcg gccggcgccg gtgagcgagg tcatcgtcct    60
gcattacaac tacaccggca agctccgctg tgcgcgctac cagccgggtg ccggcctgcg    120
cgccgacgcc gtggtgtgcc tggcggtgtg cgccctcctc gtgctagaga atctagccgt    180
gttggttggtg ctcggaaccc acccgctctt ccacgctccc atgttcctgc tcctgggcag    240
cctcaegtty tcggtgcggc cagggcccg gactgcgggg accacctcga cccgggcgcg    300
tcgcaagccg cgctcgctgg ccttgetgcy cacgetcagc gtggtgetcc tggcctttgt    360
ggcatgttgg gggccctctt tcctgctgct gttgctcgac gtggcgtgcc cggcgcgcac    420
ctgtcctgta ctctcgagc ccgatccctt cctgggactg gccatggcca actcacttct    480
gaaccccatc atctacacgc tcaccaaccg cgacctgcgc cacgcgctcc tgcgcctggt    540
ctgctgcgga cgccactcct gcggcagaga cccgagtggc tcccagcagt cggcgagcgc    600
ggctgaggct tccggggggc tgcgcccctg cctgcccccg ggcttctgat ggagcttcag    660
cggctcggag cgctcatcgc cccagcgcga cgggctggac accagcggct ccacaggcag    720
ccccggtgca cccacagccg cccggactct ggtatcagaa ccggctgcag actgacaccc    780
tcggccccacg actgtcttcc caagtcttac agacttcttc tttttacata aaggaatttg    840
taggaaatgc agccaaaggt cgagtcggaa aagatgcagg ggaaatgtat ttatgcagcg    900
acaccccaca atgtgaacaa acagacaaaa aatctgtgcc ctctgtggaat tgacgttctg    960
cttgggaaaca cagaaaagaa ctcggtgatg aaataatgga gatgattcca gtgacaaaacg   1020
acagagatgg tgatggtggt caggaagac ctctctgcag aggtagtgcac ttgtgatgtg   1080
agctgagacc tctgtcctgg gaagacaaa agaaaagcat ttcaggatga gggaaatggca   1140
tgcgcaaagg ccctgaggct gaaatgtgcc catgtgttct aagaaatgca gcgatgctgg   1200
tgtgcctgga gcagggacgg agggggagaa tgggaggaga caaggagctg aaggagtagt   1260
tcccgaagga ccttgtgggt gatatagagg acttcgcttt tgctctgagt gaggtgggag   1320
ccatagaagc ttctaagcag aagagggact tgcctaatc caggtgatca caggtgtctt   1380
gtggcctcca tgggaggttg aaaaccagag aaggtgaagg ggggtgcac tgagccacag   1440
gaacaatgat ggagattcca gctaagccca gaccccgctg attctagata gatttttagag   1500
gcagcagaca gaattactga ggaattgagt gtaagagtgg aataaagtta tcaaggacaa   1560
tgccaagggt ggggcacccc caaatttgac tctgggagac tcagccaaat cctatctggt   1620
aataaaattt cttttttatt tttctttctt ttctttcttt cttttttttt tttttgagtt   1680
gggatcttgt gctctgtc 1698

```

```

<210> SEQ ID NO 10
<211> LENGTH: 398
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens
<220> FEATURE:
<221> NAME/KEY: MISC_FEATURE

```

-continued

<223> OTHER INFORMATION: Sphingosine-1-phosphate receptor (SIP)
(Figures 14 and 15)

<400> SEQUENCE: 10

```

Met Glu Ser Gly Leu Leu Arg Pro Ala Pro Val Ser Glu Val Ile Val
1           5           10           15
Leu His Tyr Asn Tyr Thr Gly Lys Leu Arg Gly Ala Arg Tyr Gln Pro
20           25           30
Gly Ala Gly Leu Arg Ala Asp Ala Val Val Cys Leu Ala Val Cys Ala
35           40           45
Phe Ile Val Leu Glu Asn Leu Ala Val Leu Leu Val Leu Gly Arg His
50           55           60
Pro Arg Phe His Ala Pro Met Phe Leu Leu Leu Gly Ser Leu Thr Leu
65           70           75           80
Ser Asp Leu Leu Ala Gly Ala Ala Tyr Ala Ala Asn Ile Leu Leu Ser
85           90           95
Gly Pro Leu Thr Leu Lys Leu Ser Pro Ala Leu Trp Phe Ala Arg Glu
100          105          110
Gly Gly Val Phe Val Ala Leu Thr Ala Ser Val Leu Ser Leu Leu Ala
115          120          125
Ile Ala Leu Glu Arg Ser Leu Thr Met Ala Arg Arg Gly Pro Ala Pro
130          135          140
Val Ser Ser Arg Gly Arg Thr Leu Ala Met Ala Ala Ala Ala Trp Gly
145          150          155          160
Val Ser Leu Leu Leu Gly Leu Leu Pro Ala Leu Gly Trp Asn Cys Leu
165          170          175
Gly Arg Leu Asp Ala Cys Ser Thr Val Leu Pro Leu Tyr Ala Lys Ala
180          185          190
Tyr Val Leu Phe Cys Val Leu Ala Phe Val Gly Ile Leu Ala Ala Ile
195          200          205
Cys Ala Leu Tyr Ala Arg Ile Tyr Cys Gln Val Arg Ala Asn Ala Arg
210          215          220
Arg Leu Pro Ala Arg Pro Gly Thr Ala Gly Thr Thr Ser Thr Arg Ala
225          230          235          240
Arg Arg Lys Pro Arg Ser Leu Ala Leu Leu Arg Thr Leu Ser Val Val
245          250          255
Leu Leu Ala Phe Val Ala Cys Trp Gly Pro Leu Phe Leu Leu Leu Leu
260          265          270
Leu Asp Val Ala Cys Pro Ala Arg Thr Cys Pro Val Leu Leu Gln Ala
275          280          285
Asp Pro Phe Leu Gly Leu Ala Met Ala Asn Ser Leu Leu Asn Pro Ile
290          295          300
Ile Tyr Thr Leu Thr Asn Arg Asp Leu Arg His Ala Leu Leu Arg Leu
305          310          315          320
Val Cys Cys Gly Arg His Ser Cys Gly Arg Asp Pro Ser Gly Ser Gln
325          330          335
Gln Ser Ala Ser Ala Ala Glu Ala Ser Gly Gly Leu Arg Arg Cys Leu
340          345          350
Pro Pro Gly Leu Asp Gly Ser Phe Ser Gly Ser Glu Arg Ser Ser Pro
355          360          365
Gln Arg Asp Gly Leu Asp Thr Ser Gly Ser Thr Gly Ser Pro Gly Ala
370          375          380
Pro Thr Ala Ala Arg Thr Leu Val Ser Glu Pro Ala Ala Asp
385          390          395

```

-continued

<210> SEQ ID NO 11
 <211> LENGTH: 254
 <212> TYPE: PRT
 <213> ORGANISM: Homo sapiens
 <220> FEATURE:
 <221> NAME/KEY: MISC_FEATURE
 <223> OTHER INFORMATION: Sphingosine-1-phosphate receptor 1 (SIP1)
 (Figure 14)

<400> SEQUENCE: 11

Met Glu Ser Gly Leu Leu Arg Pro Ala Pro Val Ser Glu Val Ile Val
 1 5 10 15
 Leu His Tyr Asn Tyr Thr Gly Lys Leu Arg Gly Ala Arg Tyr Gln Pro
 20 25 30
 Gly Ala Gly Leu Arg Ala Asp Ala Val Val Cys Leu Ala Val Cys Ala
 35 40 45
 Phe Ile Val Leu Glu Asn Leu Ala Val Leu Leu Val Leu Gly Arg His
 50 55 60
 Pro Arg Phe His Ala Pro Met Phe Leu Leu Leu Gly Ser Leu Thr Leu
 65 70 75 80
 Ser Val Pro Ala Arg Pro Gly Thr Ala Gly Thr Thr Ser Thr Arg Ala
 85 90 95
 Arg Arg Lys Pro Arg Ser Leu Ala Leu Leu Arg Thr Leu Ser Val Val
 100 105 110
 Leu Leu Ala Phe Val Ala Cys Trp Gly Pro Leu Phe Leu Leu Leu Leu
 115 120 125
 Leu Asp Val Ala Cys Pro Ala Arg Thr Cys Pro Val Leu Leu Gln Ala
 130 135 140
 Asp Pro Phe Leu Gly Leu Ala Met Ala Asn Ser Leu Leu Asn Pro Ile
 145 150 155 160
 Ile Tyr Thr Leu Thr Asn Arg Asp Leu Arg His Ala Leu Leu Arg Leu
 165 170 175
 Val Cys Cys Gly Arg His Ser Cys Gly Arg Asp Pro Ser Gly Ser Gln
 180 185 190
 Gln Ser Ala Ser Ala Ala Glu Ala Ser Gly Gly Leu Arg Arg Cys Leu
 195 200 205
 Pro Pro Gly Leu Asp Gly Ser Phe Ser Gly Ser Glu Arg Ser Ser Pro
 210 215 220
 Gln Arg Asp Gly Leu Asp Thr Ser Gly Ser Thr Gly Ser Pro Gly Ala
 225 230 235 240
 Pro Thr Ala Ala Arg Thr Leu Val Ser Glu Pro Ala Ala Asp
 245 250

<210> SEQ ID NO 12
 <211> LENGTH: 103
 <212> TYPE: PRT
 <213> ORGANISM: Homo sapiens
 <220> FEATURE:
 <221> NAME/KEY: MISC_FEATURE
 <223> OTHER INFORMATION: Sphingosine-1-Phosphate receptor 2 (Figure 6)

<400> SEQUENCE: 12

Met Glu Ser Gly Leu Leu Arg Pro Ala Pro Val Ser Glu Val Ile Val
 1 5 10 15
 Leu His Tyr Asn Tyr Thr Gly Lys Leu Arg Gly Ala Arg Tyr Gln Pro
 20 25 30
 Gly Ala Gly Leu Arg Ala Asp Ala Val Val Cys Leu Ala Val Cys Ala
 35 40 45

-continued

Phe Ile Val Leu Glu Asn Leu Ala Val Leu Leu Val Leu Gly Arg His
 50 55 60

Pro Arg Phe His Ala Pro Met Phe Leu Leu Leu Gly Ser Leu Thr Leu
 65 70 75 80

Ser Asp Leu Leu Ala Gly Ala Ala Tyr Ala Ala Ala Arg Thr Leu
 85 90 95

Val Ser Glu Pro Ala Ala Asp
 100

<210> SEQ ID NO 13
 <211> LENGTH: 1245
 <212> TYPE: DNA
 <213> ORGANISM: Homo sapiens
 <220> FEATURE:
 <221> NAME/KEY: misc_feature
 <223> OTHER INFORMATION: Sphingosine-1-Phosphate receptor 2 (Figure 6)

<400> SEQUENCE: 13

```

cgcgcgcccc atggagtcgg ggctgctgcg gccggcgccg gtgagcgagg tcategtcct      60
gcattacaac tacacgggca agctccgctg tgccgcttac cagccgggtg cgggctgctg      120
cgccgacgcc gtgggtgctg tggcgggtg cgcttctc gtgctagaga atctagccgt      180
gttgttggtg ctccgacgcc acccgcgctt ccacgctccc atgttctctg tcttgggcag      240
cctcacgttg tcggatctgc tggcaggcgc cgctacgcc gccgccgccc ggactctggt      300
atcagaaccg gctgcagact gacaccctcg gccacgact gtcttcccaa gttttacaga      360
cttgttcttt ttacataaag gaattttagt gaaatgcagc caaaggtgca gtcggaaaag      420
atgcagggga aatgtattta tgcagcgaca ccccaaatg tgaacaaaca gacaaaaaat      480
ctgtgccctc gtggaattga cgttctgctt gggaacacag aaaagaactc ggtgatgaaa      540
taatggagat gattccagtg acaaacgaca gagatggtga tgggtggtcag ggaagacctc      600
tctgcagagg tagtgacttg tgatgtgagc tgagacctt gtcctgggaa gaccaaaga      660
aaagcatttc aggatgaggg aatggcatgc gcaaaggccc tgaggctgaa atgtgcccat      720
gtgttctaag aaatgcagcg atgctggtgt gcctggagca gggacggagg gggagaaatgg      780
gaggagacaa ggagctgaag gagtagttcc cgaaggacct tgtgggtgat atagaggact      840
tcgcttttgc tctgagttag gtgggagcca tagaagcttc taagcagaag agggacttgc      900
cctaattcag gtgatcacag gtgtcttggt gcctccatgg gaggttgaag accagagaag      960
gtgaaggggg gctgactgca gccacaggaa caatgatgga gattccagct aagcccagac     1020
cccgtggatt ctatagatg tttagaggca gcagacagaa ttactgagga attgagtgtg     1080
agagtggaat aaagtatca aggacaatgc caaggggtgg gcacccccaa atttgactct     1140
gggagactca gccaaatcct atctggtaat aaaatttctt ttttattttt cttttcttct     1200
tttcttctct tttttttttt ttgagttggg atcttctgct ctgtc                       1245

```

<210> SEQ ID NO 14
 <211> LENGTH: 103
 <212> TYPE: PRT
 <213> ORGANISM: Homo sapiens
 <220> FEATURE:
 <221> NAME/KEY: MISC_FEATURE
 <223> OTHER INFORMATION: Sphingosine-1-Phosphate receptor 2 (SIP2)
 (Figure 15)

<400> SEQUENCE: 14

Met Glu Ser Gly Leu Leu Arg Pro Ala Pro Val Ser Glu Val Ile Val
 1 5 10 15

-continued

Leu His Tyr Asn Tyr Thr Gly Lys Leu Arg Gly Ala Arg Tyr Gln Pro
 20 25 30
 Gly Ala Gly Leu Arg Ala Asp Ala Val Val Cys Leu Ala Val Cys Ala
 35 40 45
 Phe Ile Val Leu Glu Asn Leu Ala Val Leu Leu Val Leu Gly Arg His
 50 55 60
 Pro Arg Phe His Ala Pro Met Phe Leu Leu Leu Gly Ser Leu Thr Leu
 65 70 75 80
 Ser Asp Leu Leu Ala Gly Ala Ala Tyr Ala Ala Ala Ala Arg Thr Leu
 85 90 95
 Val Ser Glu Pro Ala Ala Asp
 100

<210> SEQ ID NO 15
 <211> LENGTH: 2306
 <212> TYPE: DNA
 <213> ORGANISM: Homo sapiens
 <220> FEATURE:
 <221> NAME/KEY: misc_feature
 <223> OTHER INFORMATION: Full-length (2.2 kb) nucleotide sequence of
 human S1P5 cDNA (Figure 8)

<400> SEQUENCE: 15

gcgcgcccca tggagtcggg gctgctgccc ccggcgccgg tgagcgaggt catcgtcctg 60
 cattacaact acaccggcaa gctccggcgt gcgcgctacc agccgggtgc cggcctgcgc 120
 gccgacgcgc tgggtgtgct ggcgggtgtc gccttcacgc tgetagagaa tctagccgtg 180
 ttgttggtgc tcggacgcca cccgcgcttc cacgctccca tgttctgct cctgggcagc 240
 ctcacgttgt cggatctgct ggcaggcgcc gcctacgccc ccaacatcct actgtcgggg 300
 ccgctcagcg tgaactgtc ccccgcgctc tggttcgcac gggagggagg cgtctctgtg 360
 gcactcactg cgtccgtgct gagcctcctg gccatcgcgc tggagcgag cctcaccatg 420
 gcgcgagggg ggcccgcgcc cgtctccagt cgggggcgca cgctggcgat ggcagccgcg 480
 gcctggggcg tgtcgctgct cctcgggctc ctgccagcgc tgggctggaa ttgcctgggt 540
 cgctggagcg cttgctccac tgtcttgccc ctctacgcca aggcctacgt gctcttctgc 600
 gtgctegcct tcgtgggcat cctggcgcgc atctgtgca tctacgcgc catctactgc 660
 caggtaacgc ccaacgcgcg gcgctgccc gcacggccc ggactgcggg gaccacctcg 720
 acccgggcgc gtcgaagcc gcgctcctg gccttgetgc gcacgctcag cgtggtgctc 780
 ctggcctttg tggcatgtt gggccccctc ttctgctgc tgttgetcga cgtggcgtgc 840
 ccggcgcgca cctgctctgt actcctgcag gccgatccct tctgggact ggccatggcc 900
 aactcacttc tgaaccccc catctacag ctcaccaacc gcgacctgcg ccacgcgctc 960
 ctgcgectgg tctgctgccc acgccactcc tgccgcagag acccgagtgg ctcccagcag 1020
 tcggcgagcg cggctgaggg ttccgggggc ctgcgcccgt gcctgcccc gggccttgat 1080
 gggagcttca gcgctcggg gcgctcatcg ccccagcgcg acgggctgga caccagcggc 1140
 tccacaggca gcccccgtgc acccacagcc gcccgactc tggatcaga accggctgca 1200
 gactgacacc ctgcgcccac gactgtcttc ccaagtttta cagacttggt ctttttacat 1260
 aaaggaattt gtagaaatg cagccaaagg tgcagtcgga aaagatgcag gggaaatgta 1320
 tttatgcagc gacaccccac aatgtgaaca aacagacaaa aaatctgtgc cctcgtggaa 1380
 ttgacgttct gcttgggaac acagaaaaga actcgggtgat gaaataatgg agatgattcc 1440
 agtgacaaac gacagagatg gtgatggtgg tcaggaaga cctctctgca gaggtagtga 1500

-continued

```

cttgtgatgt gagctgagac ctctgtcctg ggaagaccaa aagaaaagca tttcaggatg 1560
agggaatggc atgcgcaaag gccctgaggc tgaatgtgc ccatgtgttc taagaaatgc 1620
agcgatgctg gtgtgcctgg agcagggacg gagggggaga atgggaggag acaaggagct 1680
gaaggagtag ttcccgaagg accttgtggg tgatatagag gacttcgctt ttgctctgag 1740
tgagggtgga gccatagaag cttctaagca gaagaggac ttgccctaat tcaggatgatc 1800
acagggtgtct tgtggcctcc atggggaggtt gaaaaccaca gaaggtgaag gggggctgca 1860
ctgagccaca ggaacaatga tggagattcc agctaagccc agaccccgtg gattctagat 1920
agattttaga ggcagcagc agaattactg aggaattgag tgtaagagtg gaataaagtt 1980
atcaaggaca atgccaaggg tggggcaccc ccaaatttga ctttgggaga ctcagccaaa 2040
tcctatctgg taataaaatt tcttttttat ttttcttttc tttctttctt tctttctttc 2100
tttttttttt tttgagttgg gatcttgtgc tctgtcaccg aggctggagt gcaatgggca 2160
caattatagc tcaactgcagc ctggaactcc tgggatcaag cctggagttc ctgcttcagc 2220
ctccctagta gctgggacta caggcatgca ccaccatgcc cagttaataa aattttctca 2280
aatgcaaaaa aaaaaaaaaa aaaaaa 2306

```

<210> SEQ ID NO 16

<211> LENGTH: 398

<212> TYPE: PRT

<213> ORGANISM: Homo sapiens

<220> FEATURE:

<221> NAME/KEY: MISC FEATURE

<223> OTHER INFORMATION: Deduced amino acid sequence of human S1P5 cDNA coding region (Figure 8)

<400> SEQUENCE: 16

```

Met Glu Ser Gly Leu Leu Arg Pro Ala Pro Val Ser Glu Val Ile Val
1           5           10          15
Leu His Tyr Asn Tyr Thr Gly Lys Leu Arg Gly Ala Arg Tyr Gln Pro
20          25          30
Gly Ala Gly Leu Arg Ala Asp Ala Val Val Cys Leu Ala Val Cys Ala
35          40          45
Phe Ile Val Leu Glu Asn Leu Ala Val Leu Leu Val Leu Gly Arg His
50          55          60
Pro Arg Phe His Ala Pro Met Phe Leu Leu Leu Gly Ser Leu Thr Leu
65          70          75          80
Ser Asp Leu Leu Ala Gly Ala Ala Tyr Ala Ala Asn Ile Leu Leu Ser
85          90          95
Gly Pro Leu Thr Leu Lys Leu Ser Pro Ala Leu Trp Phe Ala Arg Glu
100         105         110
Gly Gly Val Phe Val Ala Leu Thr Ala Ser Val Leu Ser Leu Leu Ala
115         120         125
Ile Ala Leu Glu Arg Ser Leu Thr Met Ala Arg Arg Gly Pro Ala Pro
130         135         140
Val Ser Ser Arg Gly Arg Thr Leu Ala Met Ala Ala Ala Ala Trp Gly
145         150         155         160
Val Ser Leu Leu Leu Gly Leu Leu Pro Ala Leu Gly Trp Asn Cys Leu
165         170         175
Gly Arg Leu Asp Ala Cys Ser Thr Val Leu Pro Leu Tyr Ala Lys Ala
180         185         190
Tyr Val Leu Phe Cys Val Leu Ala Phe Val Gly Ile Leu Ala Ala Ile
195         200         205
Cys Ala Leu Tyr Ala Arg Ile Tyr Cys Gln Val Arg Ala Asn Ala Arg

```


-continued

Gly Arg Leu Asp Ala Cys Ser Thr Val Leu Pro Leu Tyr Ala Lys Ala
 180 185 190

Tyr Val Leu Phe Cys Val Leu Ala Phe Val Gly Ile Leu Ala Ala Ile
 195 200 205

Cys Ala Leu Tyr Ala Arg Ile Tyr Cys Gln Val Arg Ala Asn Ala Arg
 210 215 220

Arg Leu Pro Ala Arg Pro Gly Thr Ala Gly Thr Thr Ser Thr Arg Ala
 225 230 235 240

Arg Arg Lys Pro Arg Ser Leu Ala Leu Leu Arg Thr Leu Ser Val Val
 245 250 255

Leu Leu Ala Phe Val Ala Cys Trp Gly Pro Leu Phe Leu Leu Leu Leu
 260 265 270

Leu Asp Val Ala Cys Pro Ala Arg Thr Cys Pro Val Leu Leu Gln Ala
 275 280 285

Asp Pro Phe Leu Gly Leu Ala Met Ala Asn Ser Leu Leu Asn Pro Ile
 290 295 300

Ile Tyr Thr Leu Thr Asn Arg Asp Leu Arg His Ala Leu Leu Arg Leu
 305 310 315 320

Val Cys Cys Gly Arg His Ser Cys Gly Arg Asp Pro Ser Gly Ser Gln
 325 330 335

Gln Ser Ala Ser Ala Ala Glu Ala Ser Gly Gly Leu Arg Arg Cys Leu
 340 345 350

Pro Pro Gly Leu Asp Gly Ser Phe Ser Gly Ser Glu Arg Ser Ser Pro
 355 360 365

Gln Arg Asp Gly Leu Asp Thr Ser Gly Ser Thr Gly Ser Pro Gly Ala
 370 375 380

Pro Thr Ala Ala Arg Thr Leu Val Ser Glu Pro Ala Ala Asp
 385 390 395

<210> SEQ ID NO 18

<211> LENGTH: 254

<212> TYPE: PRT

<213> ORGANISM: Homo sapiens

<220> FEATURE:

<221> NAME/KEY: MISC_FEATURE

<223> OTHER INFORMATION: Predicted amino acid sequence of S1P5-alpha
(Figure 12A)

<400> SEQUENCE: 18

Met Glu Ser Gly Leu Leu Arg Pro Ala Pro Val Ser Glu Val Ile Val
 1 5 10 15

Leu His Tyr Asn Tyr Thr Gly Lys Leu Arg Gly Ala Arg Tyr Gln Pro
 20 25 30

Gly Ala Gly Leu Arg Ala Asp Ala Val Val Cys Leu Ala Val Cys Ala
 35 40 45

Phe Ile Val Leu Glu Asn Leu Ala Val Leu Leu Val Leu Gly Arg His
 50 55 60

Pro Arg Phe His Ala Pro Met Phe Leu Leu Leu Gly Ser Leu Thr Leu
 65 70 75 80

Ser Val Pro Ala Arg Pro Gly Thr Ala Gly Thr Thr Ser Thr Arg Ala
 85 90 95

Arg Arg Lys Pro Arg Ser Leu Ala Leu Leu Arg Thr Leu Ser Val Val
 100 105 110

Leu Leu Ala Phe Val Ala Cys Trp Gly Pro Leu Phe Leu Leu Leu Leu
 115 120 125

Leu Asp Val Ala Cys Pro Ala Arg Thr Cys Pro Val Leu Leu Gln Ala
 130 135 140

-continued

```

Asp Pro Phe Leu Gly Leu Ala Met Ala Asn Ser Leu Leu Asn Pro Ile
145          150          155          160
Ile Tyr Thr Leu Thr Asn Arg Asp Leu Arg His Ala Leu Leu Arg Leu
          165          170          175
Val Cys Cys Gly Arg His Ser Cys Gly Arg Asp Pro Ser Gly Ser Gln
          180          185          190
Gln Ser Ala Ser Ala Ala Glu Ala Ser Gly Gly Leu Arg Arg Cys Leu
          195          200          205
Pro Pro Gly Leu Asp Gly Ser Phe Ser Gly Ser Glu Arg Ser Ser Pro
          210          215          220
Gln Arg Asp Gly Leu Asp Thr Ser Gly Ser Thr Gly Ser Pro Gly Ala
225          230          235          240
Pro Thr Ala Ala Arg Thr Leu Val Ser Glu Pro Ala Ala Asp
          245          250
    
```

```

<210> SEQ ID NO 19
<211> LENGTH: 103
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens
<220> FEATURE:
<221> NAME/KEY: MISC_FEATURE
<223> OTHER INFORMATION: Predicted amino acid sequence of S1P5-beta
(Figure 12B)
    
```

```

<400> SEQUENCE: 19
Met Glu Ser Gly Leu Leu Arg Pro Ala Pro Val Ser Glu Val Ile Val
1          5          10          15
Leu His Tyr Asn Tyr Thr Gly Lys Leu Arg Gly Ala Arg Tyr Gln Pro
          20          25          30
Gly Ala Gly Leu Arg Ala Asp Ala Val Val Cys Leu Ala Val Cys Ala
          35          40          45
Phe Ile Val Leu Glu Asn Leu Ala Val Leu Leu Val Leu Gly Arg His
          50          55          60
Pro Arg Phe His Ala Pro Met Phe Leu Leu Leu Gly Ser Leu Thr Leu
65          70          75          80
Ser Asp Leu Leu Ala Gly Ala Ala Tyr Ala Ala Ala Ala Arg Thr Leu
          85          90          95
Val Ser Glu Pro Ala Ala Asp
          100
    
```

We claim:

1. A method of screening for rheumatoid arthritis, comprising screening a sample from a patient for over-expression of a nucleic acid molecule encoding the sphingosine 1-phosphate receptor (SPPR) protein, wherein said protein comprises the amino acid sequence of SEQ ID NO:3, and wherein over-expression of said nucleic acid molecule is indicative of rheumatoid arthritis.
2. The method of claim 1, wherein said screening comprises measuring the amount of SPPR protein in the sample.
3. The method of claim 1, wherein said screening comprises measuring the amount of mRNA of SEQ ID NO:4 in the sample.
4. A method of screening for large granular lymphocyte (LGL) leukemia, comprising screening a sample from a patient for over-expression of a nucleic acid molecule encoding the sphingosine 1-phosphate receptor (SPPR) protein,

wherein said protein comprises the amino acid sequence of SEQ ID NO:3, and wherein over-expression of the nucleic acid molecule is indicative of LGL leukemia.

5. The method of claim 4, wherein said screening comprises measuring the amount of SPPR protein in the sample.

6. The method of claim 4, wherein said sample comprises blood.

7. A method of screening for large granular lymphocyte (LGL) leukemia in peripheral blood mononuclear cells (PBMC), comprising screening a sample of PBMC from a patient for over-expression of a nucleic acid molecule encoding the SPPR protein, wherein said protein comprises the amino acid sequence of SEQ ID NO:3, and wherein over-expression of the nucleic acid molecule is indicative of LGL leukemia.

* * * * *

UNITED STATES PATENT AND TRADEMARK OFFICE
CERTIFICATE OF CORRECTION

PATENT NO. : 7,964,358 B2
APPLICATION NO. : 12/879918
DATED : June 21, 2011
INVENTOR(S) : Thomas P. Loughran and Ravi Kothapalli

Page 1 of 3

It is certified that error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

Column 1,

Line 36, "not hilly" should read --not fully--.

Column 2,

Line 17, "when compare to" should read --when compared to--.

Line 47, "renamed S1P5.

DESCRIPTION OF THE FIGURES"

should read

--renamed S1P5.

BRIEF DESCRIPTION OF THE SEQUENCES

SEQ ID NO:1 is a forward primer used according to the subject invention.

SEQ ID NO:2 is a reverse primer used according to the subject invention.

SEQ ID NO:3 is the predicted amino acid sequence of the human sphingosine 1-Phosphate receptor (SPPR) cDNA of **SEQ ID NO:4**.

SEQ ID NO:4 is the complete nucleotide sequence of human sphingosine 1-Phosphate receptor (SPPR) cDNA.

SEQ ID NO:5 is the amino acid sequence of rat nrg-1.

SEQ ID NO:6 is the amino acid sequence of rat cdg-8.

SEQ ID NO:7 is the amino acid sequence of SPPR.


SEQ ID NO:8 is the deduced amino acid sequence of splice variant, sphingosine 1-phosphate receptor 1 of **SEQ ID NO:9**.

SEQ ID NO:9 is the nucleotide sequence of splice variant, sphingosine 1-phosphate receptor 1.

SEQ ID NO:10 is the amino acid sequence of the sphingosine 1-phosphate receptor (S1P).

SEQ ID NO:11 is the amino acid sequence of the sphingosine 1-phosphate receptor 1 (S1P₁).

Signed and Sealed this
Eleventh Day of October, 2011



David J. Kappos

Director of the United States Patent and Trademark Office

U.S. Pat. No. 7,964,358 B2

SEQ ID NO:12 is the deduced amino acid sequence of splice variant, sphingosine 1-phosphate receptor 2 of **SEQ ID NO:13**.

SEQ ID NO:13 is the nucleotide sequence of splice variant, sphingosine 1-phosphate receptor 2.

SEQ ID NO:14 is the amino acid sequence of sphingosine 1-phosphate receptor 2 (S1P₂).

SEQ ID NO:15 is the full-length (2.2 kb) nucleotide sequence of human S1P5 cDNA (Figure 8).

SEQ ID NO:16 is the deduced amino acid sequence of human S1P5 cDNA coding region (Figure 8).

SEQ ID NO:17 is the predicted amino acid sequence of S1P5 (Figures 12A and 12B).

SEQ ID NO:18 is the predicted amino acid sequence of S1P5-alpha (Figure 12A).

SEQ ID NO:19 is the predicted amino acid sequence of S1P5-beta (Figure 12B).

DESCRIPTION OF THE FIGURES--.

Column 3,

Line 14, "sppr is" should read --sppr (SEQ ID NO:7) is--.

Line 15, "rat edg-1 and nrg-1. There" should read

--rat edg-1 (SEQ ID NO:6) and nrg-1 (SEQ ID NO:5). There--.

Line 17, "sequence and" should read --sequence (SEQ ID NO:9) and--.

Line 18, "sequence of" should read --sequence (SEQ ID NO:8) of--.

Line 22, "sequence and" should read --sequence (SEQ ID NO:13) and--.

Line 23, "sequence of" should read --sequence (SEQ ID NO:12) of--.

Line 40, "S1P₅ is" should read --S1P₅ (SEQ ID NO:15) is--.

Line 44, "abbreviation. The" should read --abbreviation (SEQ ID NO:16). The--.

Line 50, "S1P₅ is" should read --S1P₅ (SEQ ID NO:7) is--.

Line 51, "rat edg-8 and nrg-1. There" should read

--rat edg-8 (SEQ ID NO:6) and nrg-1 (SEQ ID NO:5). There--.

Column 4,

Line 18, "shows comparison of" should read --shows comparisons of--.

Line 19, "S1P₅-β. The" should read

--S1P₅-β (SEQ ID NO:17, SEQ ID NO:18, SEQ ID NO:19, respectively). The--.

Line 22, "sequence. A" should read --sequence (SEQ ID NO:18). A--.

Line 27, "sequence. A" should read --sequence (SEQ ID NO:19). A--.

Line 33, "poly per" should read --poly A+ per--.

Line 40, "Northern blot.)

Column 4.

Line 40, "Northern blot.)

DETAILED DESCRIPTION OF THE INVENTION"

should read

--Northern blot.)

FIGURE 14 shows a comparison of the amino acid sequences of the sphingosine-1-phosphate receptor (S1P) (SEQ ID NO:10) and the sphingosine-1-phosphate 1 receptor (S1P1) (SEQ ID NO:11).

FIGURE 15 shows a comparison of the amino acid sequences of S1P (SEQ ID NO:10) and S1P2 (SEQ ID NO:14).

DETAILED DESCRIPTION OF THE INVENTION--.

Line 53, "is represented" should read --are represented--.

Column 10.

Line 38, "Phosphorimager" should read --PhosphorImager--.

Line 61, "sample of patents" should read --sample of patients--.

Column 13.

Line 25, "this acne is" should read --this gene is--.

UNITED STATES PATENT AND TRADEMARK OFFICE
CERTIFICATE OF CORRECTION

PATENT NO. : 7,964,358 B2
APPLICATION NO. : 12/879918
DATED : June 21, 2011
INVENTOR(S) : Thomas P. Loughran and Ravi Kothapalli

Page 1 of 3

It is certified that error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

Column 1,

Line 36, "not hilly" should read --not fully--.

Column 2,

Line 17, "when compare to" should read --when compared to--.

Line 47, "renamed S1P5.

DESCRIPTION OF THE FIGURES"

should read

--renamed S1P5.

BRIEF DESCRIPTION OF THE SEQUENCES

SEQ ID NO:1 is a forward primer used according to the subject invention.

SEQ ID NO:2 is a reverse primer used according to the subject invention.

SEQ ID NO:3 is the predicted amino acid sequence of the human sphingosine 1-Phosphate receptor (SPPR) cDNA of **SEQ ID NO:4**.

SEQ ID NO:4 is the complete nucleotide sequence of human sphingosine 1-Phosphate receptor (SPPR) cDNA.

SEQ ID NO:5 is the amino acid sequence of rat nrg-1.

SEQ ID NO:6 is the amino acid sequence of rat edg-8.


SEQ ID NO:7 is the amino acid sequence of SPPR.

SEQ ID NO:8 is the deduced amino acid sequence of splice variant, sphingosine 1-phosphate receptor 1 of **SEQ ID NO:9**.

SEQ ID NO:9 is the nucleotide sequence of splice variant, sphingosine 1-phosphate receptor 1.

This certificate supersedes the Certificate of Correction issued October 11, 2011.

Signed and Sealed this
Twenty-seventh Day of March, 2012



David J. Kappos
Director of the United States Patent and Trademark Office

SEQ ID NO:10 is the amino acid sequence of the sphingosine 1-phosphate receptor (S1P).

SEQ ID NO:11 is the amino acid sequence of the sphingosine 1-phosphate receptor 1 (S1P₁).

SEQ ID NO:12 is the deduced amino acid sequence of splice variant, sphingosine 1-phosphate receptor 2 of SEQ ID NO:13.

SEQ ID NO:13 is the nucleotide sequence of splice variant, sphingosine 1-phosphate receptor 2.

SEQ ID NO:14 is the amino acid sequence of sphingosine 1-phosphate receptor 2 (S1P₂).

SEQ ID NO:15 is the full-length (2.2 kb) nucleotide sequence of human S1P5 cDNA (Figure 8).

SEQ ID NO:16 is the deduced amino acid sequence of human S1P5 cDNA coding region (Figure 8).

SEQ ID NO:17 is the predicted amino acid sequence of S1P5 (Figures 12A and 12B).

SEQ ID NO:18 is the predicted amino acid sequence of S1P5-alpha (Figure 12A).

SEQ ID NO:19 is the predicted amino acid sequence of S1P5-beta (Figure 12B).

DESCRIPTION OF THE FIGURES--.

Column 3.

Line 14, "sppr is" should read --sppr (SEQ ID NO:7) is--.

Line 15, "rat edg-1 and nrg-1. There" should read

--rat edg-1 (SEQ ID NO:6) and nrg-1 (SEQ ID NO:5). There--.

Line 17, "sequence and" should read --sequence (SEQ ID NO:9) and--.

Line 18, "sequence of" should read --sequence (SEQ ID NO:8) of--.

Line 22, "sequence and" should read --sequence (SEQ ID NO:13) and--.

Line 23, "sequence of" should read --sequence (SEQ ID NO:12) of--.

Line 40, "S1P₅ is" should read --S1P₅ (SEQ ID NO:15) is--.

Line 44, "abbreviation. The" should read --abbreviation (SEQ ID NO:16). The--.

Line 50, "S1P₅ is" should read --S1P₅ (SEQ ID NO:7) is--.

Line 51, "rat edg-8 and nrg-1. There" should read

--rat edg-8 (SEQ ID NO:6) and nrg-1 (SEQ ID NO:5). There--.

Column 4.

Line 18, "shows comparison of" should read --shows comparisons of--.

Line 19, "S1P₅-β. The" should read

--S1P₅-β (SEQ ID NO:17, SEQ ID NO:18, SEQ ID NO:19, respectively). The--.

Line 22, "sequence. A" should read --sequence (SEQ ID NO:18). A--.

Line 27, "sequence. A" should read --sequence (SEQ ID NO:19). A--.

Line 33, "poly per" should read --poly A+ per--.

Column 4.

Line 40, "Northern blot.)

DETAILED DESCRIPTION OF THE INVENTION"

should read

--Northern blot.)

FIGURE 14 shows a comparison of the amino acid sequences of the sphingosine-1-phosphate receptor (S1P) (SEQ ID NO:10) and the sphingosine-1-phosphate 1 receptor (S1P1) (SEQ ID NO:11).

FIGURE 15 shows a comparison of the amino acid sequences of S1P (SEQ ID NO:10) and S1P2 (SEQ ID NO:14).

DETAILED DESCRIPTION OF THE INVENTION--.

Line 53, "is represented" should read --are represented--.

Column 10.

Line 38, "Phosphorimager" should read --PhosphorImager--.

Line 61, "sample of patents" should read --sample of patients--.

Column 13.

Line 25, "this acne is" should read --this gene is--.

专利名称(译)	鞘氨醇1-磷酸受体基因, SPPR		
公开(公告)号	US7964358	公开(公告)日	2011-06-21
申请号	US12/879918	申请日	2010-09-10
[标]申请(专利权)人(译)	南佛罗里达大学		
申请(专利权)人(译)	南佛罗里达大学		
当前申请(专利权)人(译)	南佛罗里达大学		
[标]发明人	LOUGHRAN THOMAS P KOTHAPALLI RAVI		
发明人	LOUGHRAN, THOMAS P. KOTHAPALLI, RAVI		
IPC分类号	C12Q1/68 G01N33/53 C07K14/705 C12N15/12		
CPC分类号	C07K14/705		
优先权	60/257119 2000-12-22 US		
其他公开文献	US20110021375A1		
外部链接	Espacenet USPTO		

摘要(译)

一种新颖的鞘氨醇1-磷酸受体基因, 本文称为sppr, 及其剪接变体。
Sppr在LGL中上调, 并且可用于例如某些淋巴组织增生, 神经变性和自身免疫疾病的诊断和治疗。

